Search this site

Ambient Voice Technology in Healthcare: Predictions for 2026 Executive Summary: The Silent Revolution in Healthcare Ambient Voice Technology (AVT), once considered a speculative innovation, is rapidly evolving into a strategic necessity for healthcare organizations. Fuelled by an urgent need to combat clinician burnout, address rising administrative workloads, and enhance operational efficiency, AVT is poised to fundamentally reshape the clinical workflow. The market is transitioning from an experimental phase to a mature, regulated ecosystem where this technology is no longer a luxury but a foundational layer of modern care delivery. Key predictions for 2026 indicate a period of explosive growth and maturation. The analysis suggests that AVT adoption will reach critical mass, with an estimated 320% increase in implementation plans among healthcare executives. Financially, the technology's value proposition will be irrefutable, proving to be not only a cost-saver by reducing administrative overhead but also a direct driver of new revenue through increased patient throughput and higher coding accuracy. This market expansion, however, will be met with a maturing and increasingly stringent regulatory landscape, exemplified by the UK’s reclassification of AVT as a medical device (SaMD). This will force vendors and health systems to prioritise robust governance and compliance to mitigate clinical and legal risks. Looking beyond mere documentation, the technology will evolve into a proactive clinical partner, integrating with wearables, providing real-time decision support, and orchestrating entire clinical workflows. The ultimate success of this transformation will hinge on addressing critical challenges related to patient trust, algorithmic bias, and seamless interoperability, turning these hurdles into opportunities for competitive differentiation and long-term value creation. The Foundation: Defining Ambient Voice Technology and Its Value A New Paradigm of Clinical Documentation Ambient Voice Technology, also referred to as Ambient Clinical Intelligence (ACI) or ambient listening, represents a new paradigm for clinical documentation. It is an artificial intelligence-driven tool that operates unobtrusively in the background, passively capturing and transforming natural conversations between a clinician and a patient. The technology leverages a sophisticated combination of automatic speech recognition (ASR), large language models (LLMs), and clinical knowledge graphs to interpret the spoken dialogue and convert it into a structured, well organised clinical note. This process is fundamentally different from traditional voice recognition systems, which often require active commands, structured dictation, and extensive user training. While older systems functioned as basic dictation tools for data entry, modern AVT is designed to understand context, differentiate speakers, and filter clinically relevant information from casual conversation without interrupting the natural flow of the encounter. The problem this technology aims to solve is a national-level crisis: the administrative burden that leads to widespread clinician burnout. Physicians often find themselves spending more time on paperwork than on direct patient care, with documentation tasks consuming significant "Pajama Time" after hours. By automating this time-consuming work, AVT directly addresses a root cause of professional dissatisfaction and inefficiency. The technology is projected to free up an average of 35 minutes per clinician each day and reduce documentation time per note by up to 75%. This reclaimed time allows providers to focus on what matters most: the patient in front of them. Value Proposition for Stakeholders The value of Ambient Voice Technology extends far beyond a simple productivity boost, creating significant benefits for both clinicians and patients. For clinicians, the quantitative and qualitative benefits are substantial. The technology reduces after-hours work by up to 70% and lowers the cognitive load associated with documentation, directly mitigating burnout. More importantly, it enables clinicians to shift their attention away from a computer screen and towards the patient, fostering more meaningful and effective interactions. This improved presence and focus are a core benefit frequently cited by physicians who have adopted the technology. For patients, the impact is equally profound. When a physician is not preoccupied with typing or staring at a screen, patients report feeling more engaged, heard, and that their doctor truly understood their concerns.This enhanced interaction improves patient satisfaction and can even lead to better adherence to treatment plans, as trust and clear communication are foundational to the patient-physician relationship. The effectiveness of this technology is rooted in a powerful, symbiotic relationship: the reduction of clinician burden directly enables an improved patient experience. The technology's dual-sided value proposition is a key driver of its rapid adoption, as it simultaneously addresses the business imperative of efficiency and the human imperative of quality care. A Market in Momentum: Adoption, Investment and ROI Market Size and Investment Forecasts The ambient AI market is currently in a state of rapid expansion, with predictions pointing to an unprecedented infusion of capital and a clear trajectory toward becoming a multi-billion dollar segment by 2026. The investment community has recognised the technology's potential, pouring nearly $1 Billion into ambient AI companies in 2025 alone, positioning it as one of the most successful use cases for AI in healthcare to date. While market size projections vary based on definition, the collective data signals explosive growth. For instance, some forecasts place the global AI in healthcare market at over $8 Billion by 2026, while the broader conversational AI market is projected to reach $16.9 Billion by 2025. Regardless of the specific numbers, the trend is clear: significant investment is fuelling a period of rapid innovation and market consolidation, indicating that ambient voice technology is becoming a foundational element of healthcare IT infrastructure. The Tipping Point: From Early Adopters to Widespread Implementation By 2026, ambient voice technology is expected to move from an experimental tool to a standard component of clinical practice in many settings. A survey of 130 healthcare executives revealed a 320% growth in planned implementation for clinical documentation AI by 2026, with the number of organisations planning to adopt the technology jumping from 10% to 42%. This shift signifies the "part two" of AI's adoption story in healthcare, where the focus expands from revenue-related functions like scheduling and coding to historically problematic areas like clinical documentation and clinician satisfaction. While organisations are adopting the technology at an "unprecedented rate," clinician adoption is still in "very early stages" in some cases, particularly in acute care settings. This suggests that the initial phase of market growth is driven by top-down, C-suite mandates and pilot programs, which are then expected to lead to the predicted high adoption rates. The next phase of adoption, crucial for reaching the predicted 75% to 80% utilisation rates seen in some early-adopter organisations, will depend on successful change management and a clear demonstration of value to frontline providers. This requires a bottom-up approach where a positive experience, shared through word-of-mouth among clinicians, becomes the primary driver of broader adoption. The Financial Imperative: ROI and Revenue as Key Drivers The financial case for ambient voice technology is becoming indisputable, fundamentally changing the narrative from a cost center to a direct revenue driver. The quantitative data on cost savings is compelling. Ambient AI scribes typically cost between $49 and $199 monthly per provider, representing a 60% to 75% cost savings when compared to a human scribe. This automation also eliminates the need for expensive transcription services, which can add thousands of dollars in annual costs per provider. However, the most powerful metric for healthcare executives is the potential for new revenue generation. By reducing documentation time, the technology enables physicians to see more patients in a given day. The analysis shows that adding just two extra patients daily can generate $104,000 in additional annual revenue per physician. This tangible financial return, coupled with significant operational gains, makes a compelling case for investment. The following table provides a consolidated view of the projected financial and operational impact of ambient AI, demonstrating its multifaceted value proposition for healthcare systems. Navigating the Vendor Landscape The Dominant Players and Their Strategic Differentiators By 2026, the ambient voice technology market will likely see a clear consolidation, with a handful of dominant players distinguishing themselves through strategic EHR integrations and specialisation. Microsoft, following its acquisition of Nuance, has emerged as a major player, offering its Dragon Copilot solution. Abridge, Ambience Healthcare, and Suki are also noted as dominant startups that have raised significant funding rounds in 2025. The primary competitive differentiator among these vendors is deep, bidirectional EHR integration. The Epic Workshop partnership between Microsoft and Abridge is a notable example, allowing them to develop native integrations that are highly valued by Epic-using organisations. Ambience Healthcare boasts seamless integration with Epic's Hyperdrive and Haiku, using native FHIR APIs to read and write information directly into the EHR without manual data entry. Similarly, Suki highlights its "bidirectional, read/write capabilities" with all leading EHRs, allowing clinicians to pull pre-charted information and vitals into their notes, eliminating the need for copy-paste. Beyond integration, vendors are specializing to meet the unique needs of different clinical workflows. Ambience Healthcare, for example, has adapted its platform to the language, priorities, and workflows of over 200 specialties, including complex and underserved domains like oncology and psychiatry. Suki, described as a "true assistant," goes beyond note generation to recommend codes, generate orders, and answer clinical questions, positioning itself as a comprehensive tool for workflow orchestration. Vendor Name Key Differentiators EHR Integrations Noteworthy Partnerships / Funding Microsoft/Nuance Dragon Copilot, native integrations, analytics capabilities Epic, Oracle Health Epic Workshop Partnership Abridge Deep clinical/operational workflow focus, prior authorization support, evidence-traceability Epic Epic Workshop Partnership, $150M Series C Ambience Healthcare Adapts to 200+ specialties, strong focus on revenue integrity and coding Epic, native FHIR APIs Featured in Epic Toolbox Suki Bidirectional read/write with all major EHRs, order staging, Q&A Epic, Oracle Health, athenahealth, Meditech, Zoom $70M Series D in late 2024, Zoom Ventures investment Emerging and Strategic Plays from Big Tech While startups focus on gaining market share through deep EHR integrations, big tech companies are making foundational moves that could reshape the long-term landscape of healthcare AI. These players are not simply building scribes; they are prototyping the next generation of ambient intelligence. OpenAI's partnership with Penda Health in Kenya to deploy a clinical copilot is a clever strategic move. Low-resource environments provide a perfect testbed with lean workflows, simpler documentation needs, and fewer legal roadblocks. The lessons learned in these constrained settings can be used to quietly shape the next iteration of the clinical copilot that will eventually show up in developed markets like Boston or Berlin. This approach allows for rapid prototyping and validation of core technology outside of highly regulated environments. Simultaneously, Google's quiet unveiling of SensorLM, a foundation model trained not on clinical notes but on wearable sensor data, marks a subtle but significant shift. The future of healthcare AI is not just in parsing documents, but in understanding physiology, passively, continuously, and in real-time, using data from heart rates, sleep cycles, and gait changes. This development lays the groundwork for a new generation of ambient diagnostics and chronic disease monitoring. The existence of such technology in a "regulatory grey zone" highlights the tension between rapid innovation and the need for oversight, a challenge the industry will need to navigate carefully. The Reality Check: Navigating Critical Challenges The Trust Conundrum: Patients, Providers and Privacy Despite the significant benefits, the widespread adoption of ambient voice technology faces substantial challenges, particularly concerning trust, privacy, and data security. The continuous collection of sensitive data raises fundamental ethical questions, including patient privacy and data management. It is an ethical and legal obligation to obtain transparent, informed consent from patients before a consultation is recorded, as some may feel uncomfortable or even withhold critical information if they are not properly informed. For healthcare organisations, this requires stringent measures, including the encryption of Protected Health Information (PHI) both at rest and in transit, and a thorough vetting of vendors to ensure they comply with regulations like HIPAA by signing Business Associate Agreements (BAAs). The psychological impact of "always-on microphones" and the fear of surveillance is a vital human-factors challenge that goes beyond technical implementation. The success of this technology depends on its ability to fade into the background and enhance human connection by freeing up the clinician's attention, rather than creating a new layer of anxiety. The Clinical Risk: Hallucinations and Automation Bias A significant clinical risk is the potential for errors in AI-generated content. As general-purpose LLMs are built for linguistic plausibility rather than absolute truth, they can "hallucinate" or invent text that was never spoken. These errors can have severe consequences, from misdiagnoses to incorrect prescriptions, as demonstrated in early trials by the FDA and NHS. A related and perhaps more insidious risk is "automation bias," which describes a provider's tendency to overly rely on the AI's output without careful review. The high accuracy rates of 95% to 98% claimed by vendors can paradoxically increase this risk. The more "perfect" the AI seems, the less likely a human is to check its work. This places an immense burden on health systems to establish robust governance and audit protocols, and it underscores the industry's consensus that AVT must function as a "human-in-command" (HIC) tool, not an autonomous one. The clinician remains solely responsible for the accuracy and integrity of the patient's medical record, making vigilant oversight a non-negotiable part of the new workflow. The Regulatory Reckoning: Reclassifying AI as a Medical Device The regulatory landscape is maturing rapidly, and in 2026, it will be defined by a global divergence in regulatory approaches. The UK's reclassification of summarisation-capable ambient voice technology as a Software as a Medical Device (SaMD) in April 2025 is a game-changing precedent. This reclassification subjects AVT to stringent requirements, including registration with the Medicines and Healthcare products Regulatory Agency (MHRA), clinical safety assessments, and the maintenance of a detailed technical file. The UK's national chief clinical information officer issued a Priority Notification in June 2025 requiring the immediate cessation of non-compliant tools, warning that continued use could make both organisations and individual clinicians personally liable for any resulting harm. This aggressive, patient-safety-driven stance contrasts with the FDA's more measured approach in the United States, which has focused on creating a framework for AI in drug development and exploring methods to "tag" devices that use LLMs for transparency. The UK is effectively acting as a "regulatory testbed," sending a powerful signal that vendors and health systems can no longer treat compliance as an afterthought. This shift will mature the market by forcing vendors to invest in rigorous regulatory strategies, moving away from a "move fast and break things" startup culture to one of meticulous compliance and evidence-based development. Predictions for 2026 and Beyond: Beyond the Scribe The Shift from Reactive Documentation to Proactive Intelligence By 2026, ambient voice technology is predicted to evolve from a passive scribe into an active clinical partner, providing real-time intelligence at the point of care. The next generation of platforms will move beyond simply generating notes to offering real-time diagnostic nudges and prompts, such as "Ask about β-blockers," which could eventually reach an FDA-cleared decision support class. This evolution will be driven by multi-modal integrations, where AVT is combined with other data streams. For example, the development of foundation models like Google's SensorLM, trained on wearable sensor data, could enable predictive diagnostics by analysing heart rates, sleep cycles, and gait changes in conjunction with a patient's voice data. Ultimately, the technology is poised to become an "ambient OS layer" that orchestrates the entire clinical workflow, moving beyond a single note. This will include automated tasks such as generating lab orders, drafting prior authorisations, and suggesting billing codes based on the ambient conversation. The clinician's role will shift from a data entry clerk to an editor and strategic decision maker, with the AI handling the rote work and freeing up time for what truly matters: clinical judgment and patient interaction. Expanding Use Cases and Ecosystems Ambient voice technology is expected to proliferate into new, more complex clinical environments beyond its current primary and ambulatory care strongholds. In mental health, ambient AI could be used to capture conversational transcripts and tag emotional cues, providing valuable insights for therapists. In high-pressure surgical settings, the technology will support hands-free documentation and allow surgeons to access records without breaking sterility. Furthermore, AVT will become a critical component of remote patient monitoring and population health management, enabling proactive, personalized outreach for chronic disease management, medication adherence, and emergency response, such as during extreme weather events. The Future of the Clinician: A Reclaimed Focus The ultimate promise of ambient voice technology is to fundamentally reshape the clinician's role, enabling a return to a truly patient-centric practice. The new human-AI partnership will redefine the clinician's job from a data entry clerk to an editor and strategic decision-maker, with the AI handling the rote administrative tasks. The "human-in-command" model is the new standard of care. This partnership will give clinicians the time and cognitive bandwidth to focus on the human aspects of care: maintaining eye contact, practicing empathy, and applying strategic clinical judgment. Conclusion: The Road Ahead Ambient Voice Technology is not merely a tool; it is a foundational layer for a more efficient, profitable, and ultimately, more human centred healthcare system. The journey to 2026 will be defined by a delicate balance between rapid innovation and responsible governance. For healthcare leaders, success will hinge on a thoughtful and strategic approach. The analysis recommends prioritizing deep EHR integration over standalone tools to ensure a seamless workflow and maximum value. It is also crucial to invest in robust change management and transparent communication with patients and staff to build trust and encourage bottom-up adoption. Finally, health systems must implement strict governance and oversight protocols to mitigate the risks of automation bias and ensure the clinician remains in full control of the patient record. For technology vendors, the path forward requires a new level of maturity. The analysis suggests a heavy investment in regulatory compliance and evidence-traceability, particularly in light of the UK's reclassification of AVT as a medical device. Developing and fine-tuning models with diverse, domain-specific data will be essential to reduce bias and hallucinations, which are major barriers to trust and safety. For policymakers and regulators, the challenge is to develop clear, agile frameworks that promote innovation while prioritising patient safety and data privacy. The UK's approach offers a precedent, and collaboration between regulators and industry is paramount to ensure that the rapid advancements in AI can be harnessed for the benefit of all stakeholders without compromising the core principles of ethical and safe care. The future of healthcare is speaking, and the industry is finally ready to listen. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025 > October 27th-30th 2025, Riyadh, Saudi Arabia Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors invited to speak on the Investor Forum at the Global Health Exhibition 2025 in Riyadh, Saudi Arabia #GHE25 Nelson Advisors Partner Lloyd Price invited to speak on the Investor Forum at the Global Health Exhibition 2025 in Riyadh, Saudi Arabia #GHE25 Investor Forum The Investor Forum at the Global Health Exhibition 2025 is a premier platform for investors, innovators, and healthcare leaders to explore transformative investment opportunities in Saudi Arabia’s rapidly evolving healthcare landscape. Set in Riyadh, this forum aligns with Saudi Arabia’s Vision 2030, positioning the Kingdom as a global hub for healthcare investment and innovation. Whether you are interested in biotech, digital health, or expanding healthcare infrastructure, the Investor Forum offers unparalleled insights into the future of healthcare investments. Nelson Advisors invited to speak on the Investor Forum at the Global Health Exhibition 2025 in Riyadh, Saudi Arabia #GHE25 The Global Health Exhibition 2025 The Global Health Exhibition in Riyadh is a major event focused on healthcare innovation, investment, and transformation. It brings together global leaders from both the public and private sectors to discuss the future of healthcare. The exhibition features: Conferences: Including a Leaders Summit for high-level discussions, a Medical Excellence Forum, a Digital Health Forum, and a Venture Forum. Exhibition Floor: Showcasing the latest in healthcare technology, including digital health, AI, medical devices, and more. Networking: Opportunities for professionals, investors, and innovators to connect and explore partnerships. The event will take place from October 27-30, 2025, at the Riyadh Exhibition and Convention Center in Malham, Saudi Arabia.bringing together 1,000+ global presenters, 1,500+ exhibitors, and leading investors. The event capitalises on Saudi Arabia's dynamic healthcare market and its strategic position as a global investment hub. The event combines CME-accredited conferences, cutting-edge technology showcases, and exclusive investment forums, making it the definitive platform where healthcare innovation meets commercial opportunity in one of the world's most rapidly evolving markets. Nelson Advisors invited to speak on the Investor Forum at the Global Health Exhibition 2025 in Riyadh, Saudi Arabia #GHE25 Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025 > October 27th-30th 2025, Riyadh, Saudi Arabia Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors interviewed by Digital Health for their 'NHS App to unleash its full potential' story Nelson Advisors partner Lloyd Price interviewed by Digital Health for their 'NHS App to unleash its full potential' story. https://www.digitalhealth.net/2024/09/call-for-nhs-app-to-reach-its-potential-following-lord-darzi-critique/ Healthcare leaders have urged NHS England to unleash the full potential of the NHS App, following critique from Lord Ara Darzi. Lord Darzi’s independent investigation into the state of the NHS in England, published on 12 September 2024, said that the app is “not delivering a ‘digital-first’ experience similar to that found in many aspects of daily life, although there is huge potential”. Despite the Covid-19 pandemic leading to a rapid increase in registrations and nearly 80% of adults are now registered, Lord Darzi highlights that less than 20% of patients use the app monthly. He adds that although there has been “growth in ordering repeat prescriptions and managing hospital appointments”, only 1% of GP appointments are managed via the app. “With the huge success in registrations, an important opportunity is being missed to improve both efficiency and patient experience,” Lord Darzi writes. Responding to Lord Darzi’s comments, Dr Layla McCay, director of policy at NHS Confederation, said: “The task is to continuously develop the app so that patients can really have their health in their own hands, which will have significant patient and efficiency benefits. “This includes possible integration with other smartphone apps and wearable technology, improving and supporting mental wellbeing with access to digital talking therapies, strengthening two-way communication between patients and the NHS.” Dr McCay emphasised the importance of communicating the benefits of the app across all communities to increase its “usability and success”, adding that it could be used to help children access services and “get the care and support they need – particularly dental and mental health care”. Lloyd Price, partner at Nelson Advisors and health tech founder, said that the NHS App needs a “killer feature” to increase its usage and “unlock further organic and viral growth”. He added that the main functions of the NHS App to book GP appointments and order repeat prescriptions can be done through other apps such as Patient Access from EMIS, MyGP from iPlato and AirMid from TPP. Price called for the app to include “a unique and proprietary function not available on other platforms, for example waiting list validation management for outpatient appointments or average waiting times at my local A&E department”. Joe Harrison, chief executive of Milton Keynes University Hospital NHS Foundation Trust, who oversaw development of the NHS App, told Digital Health News that he is pleased that Lord Darzi has highlighted its potential. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025 > October 27th-30th 2025, Riyadh, Saudi Arabia Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

HealthTech Europe 2026: A Strategic Report on Key Priorities for Founders, Investors, Buyers, and Sellers Executive Summary: The Strategic Imperative for HealthTech in Europe 2026 The European HealthTech market in 2026 is at a pivotal juncture, moving from a period of early-stage experimentation to a more grounded, results-oriented reality. Success for all stakeholders—from innovative founders to strategic buyers—is predicated on navigating a complex and converging landscape defined by regulatory maturation, a selective funding environment, and an accelerated trend of market consolidation. The core thesis of this report is that a strategic shift is required: compliance is not a mere cost of doing business but a critical competitive advantage, and business models must demonstrate tangible, evidence-based value to unlock capital and secure exits. For Founders, the primary priority is to build for demonstrable clinical and financial value from inception. This involves designing solutions that address real-world health system pain points, such as chronic disease management or staff shortages, and rigorously validating them with measurable outcomes. Critically, founders must view the converging European regulatory frameworks, including the Medical Devices Regulation (MDR), the EU AI Act, and the European Health Data Space (EHDS), as strategic assets rather than burdens. A deep understanding of these rules and the ability to achieve compliance provides a defensible moat that is highly attractive to potential investors and acquirers. Investors are moving toward a "selective scale" funding model. Their priorities for 2026 are to deploy capital into companies with clear reimbursement pathways, robust AI-first pipelines, and a tangible, data-driven path to profitability. The strong and maturing M&A environment offers a more predictable and robust exit landscape, de-risking their investments and making the sector particularly attractive for strategic capital. Investors will capitalise on the robust M&A activity to secure strategic exits for high-quality portfolio companies. For Buyers, the strategic imperative is to acquire high-quality assets that complement their existing portfolios and accelerate their technological capabilities. This means prioritising companies with proven AI-driven solutions, robust data monetisation capabilities, and clear alignment with value-based care models. Buyers are leveraging favorable economic conditions and a deal-friendly regulatory stance to pursue strategic consolidation. Conversely, Sellers must position their companies as premium assets to command a favorable valuation and a strategic exit. This is achieved by proving regulatory readiness, demonstrating a positive care effect through clinical evidence, and aligning with the strategic imperatives of potential acquirers, such as a focus on value-based care, portfolio consolidation, or AI integration. For many, a strategic exit is the key alternative to risking obsolescence in a market that is consolidating at an accelerated pace. The European HealthTech Landscape in 2026: A Foundational Analysis Market Context and Macro Drivers The European HealthTech market is experiencing a period of profound transformation, with a compelling forecast for sustained and significant growth. The European digital health market, valued at USD $96.68 billion in 2025, is projected to reach USD $222.22 billion by 2030, advancing at an impressive compound annual growth rate (CAGR) of 18.11%. Within this, the healthcare analytics segment alone is expected to register a 19% CAGR during the forecast period. This expansion is not a fleeting trend but is fundamentally driven by deep-seated, systemic pressures on European healthcare systems. Foremost among these drivers are the region's aging population and the escalating burden of chronic diseases, which consume more than 70% of health spending. Simultaneously, Europe faces a projected clinician shortfall of 1.8 million by 2030, a demographic challenge that necessitates a fundamental shift in how care is delivered and managed. The widespread adoption of advanced technologies is no longer a luxury but a strategic necessity to address these challenges by improving operational efficiency, enabling remote care, and providing data-driven insights to clinicians. The market's growth, therefore, is directly responding to these enduring structural problems. This indicates a strong, foundational demand for digital health solutions that is largely insulated from short-term economic fluctuations. Business models and investments that directly address these core issues, such as those focused on chronic disease management, administrative automation, and alleviating staff shortages—are uniquely positioned for long-term success. The "Acquisition or Obsolescence" Dynamic A defining feature of the European HealthTech landscape in 2026 is the robust trend of mergers and acquisitions (M&A), presenting a stark choice for many companies: "be acquired or risk becoming obsolete". This dynamic is a signal of a maturing market, moving away from a fragmented state to one where high-quality, strategically aligned assets are highly sought after. The surge in M&A activity is driven by a number of factors, including a more deal-friendly stance from regulatory bodies and falling interest rates, which make acquisitions more financially attractive for strategic and financial buyers. Large corporations, both within and outside the healthcare sector, view acquisitions as a strategic imperative to optimize their portfolios and quickly gain access to new technologies, talent, and market share. For example, tech giants like Microsoft are actively acquiring healthtech founders and startups to bolster their AI divisions.Similarly, large biopharma players are adopting a "string-of-pearls" strategy, acquiring early- to mid-stage innovators to strengthen pipelines and fill capability gaps. Private equity (PE) and venture capital (VC) firms are also key players, driving consolidation through "platform acquisitions and 'bolt-on' deals". This robust PE activity is a significant force, with buyout deals in European healthcare surging by a substantial 276% year-to-date in 2025. This M&A prevalence provides a more predictable and robust exit environment for investors, thereby de-risking their capital deployment in the sector. For founders, it turns a potential funding challenge into a clear strategic path toward a premium exit. The Pillars of the Ecosystem The market's evolution is supported by three foundational pillars: technological evolution, regulatory maturation, and financial realignment. Technological Evolution: Artificial Intelligence (AI) is the dominant technological force, acting as the primary magnet for both investment and M&A activity. Companies with proprietary AI algorithms and scalable platforms are attracting heightened interest from buyers and can command premium multiples, with revenue multiples of 6-8x reported, significantly above the sector average of 4.5-5x. AI is revolutionising diagnostics, drug discovery, predictive analytics, and administrative automation. Other key areas of technological advancement include Remote Patient Monitoring (RPM), which is experiencing surging demand for home-based and hybrid care models, and blockchain technology, which is maturing as a solution for patient data security and interoperability. Regulatory Maturation: This is the most complex and defining force shaping the market. The EU's regulatory landscape is not a collection of isolated rules but a layered, interconnected framework. By 2026, the transition periods for the MDR and IVDR will end, making full compliance mandatory for all devices to remain on the market. Additionally, the EUDAMED database will be fully deployed, demanding new levels of digital transparency. The landmark EU AI Act, a binding regulation, will require companies to prepare for full compliance with its obligations for "high-risk" AI systems, which include medical devices. Finally, the European Health Data Space (EHDS), published in March 2025, is a foundational legal framework establishing rules for both patient-controlled access (primary use) and secure data reuse for research and innovation (secondary use). This multi-layered complexity serves as a significant barrier to entry, but for companies that can successfully navigate it, it creates a powerful and defensible competitive moat that is highly attractive to investors and buyers. Financial Realignment: The market has shifted from a period of "exuberance to a more grounded reality," with investors prioritising "proven business models" and demanding tangible outcomes and profitability over aggressive, unsustainable growth. This is a direct response to a cooler venture market and rising capital costs. However, public funding initiatives, such as the EU4Health Work Programme for 2026 and Horizon Europe, are providing critical, non-dilutive capital to de-risk innovation and accelerate the digitalisation of healthcare. European HealthTech Market Forecast & Macro Drivers (2024-2030) Market Segment Digital Health Healthcare Analytics Key Macro Drivers Aging Demographics Clinician Shortfall Government Initiatives Technological Advancements Priorities for Founders: Building for Traction, Not Just Headlines Product-Market Fit in a Maturing Market In a more selective funding environment, founders must move beyond a focus on visibility and headlines and instead build for tangible traction. This requires developing clinically validated, evidence-based solutions that demonstrate measurable outcomes and address "real-world health system priorities" such as improving access, affordability, and accountability. A deep understanding of provider workflows and payer pain points is essential to creating solutions that integrate seamlessly and solve a genuine need. The market is now demanding a shift from early-stage experimentation to scalable, proven business models. Navigating the Regulatory Gauntlet Regulatory compliance is no longer a peripheral concern for founders; it is a core business function and a strategic imperative. The European regulatory landscape is becoming increasingly comprehensive and interconnected, creating a powerful, defensible competitive moat for those who master it. The following regulations are key for 2026: Medical Device Regulation (MDR) & In Vitro Diagnostic Regulation (IVDR): The transition periods for these regulations will end by 2026, making it a critical year for full compliance. All devices must be MDR/IVDR compliant to remain on the market. The full deployment of the EUDAMED database will demand digital transparency for all devices. The EU AI Act: As a binding EU Regulation, the EU AI Act (EU 2024/1689) will directly apply to all member states. The obligations for "high-risk" AI systems, which include AI-powered medical devices, will become applicable 36 months after the act's entry into force. This means that by 2026, companies must be actively preparing for and planning their compliance strategies. The European Health Data Space (EHDS): Published in March 2025, the EHDS is a foundational framework aimed at creating a single market for electronic health data. It empowers individuals with greater control over their data while also enabling secure, structured access for research and innovation. For founders, this means designing solutions with a "privacy-by-design" approach that ensures compliance with GDPR, the EHDS, and other data frameworks. The ability to ethically and securely leverage data for applied research is a major value driver. The convergence of these regulations means that a single product, such as a Software as a Medical Device (SaMD) with an AI algorithm, must navigate the MDR/IVDR for product safety, the GDPR for data protection, the EHDS for data interoperability, and the EU AI Act for the algorithm itself. This multi-layered complexity presents a significant barrier to entry, but for founders who successfully navigate it, the compliance "passport" they achieve serves as a powerful, defensible differentiator that is highly valued by investors and buyers. It demonstrates legitimacy and the potential for continent-wide scaling and data interoperability. Key European Regulations Impacting HealthTech in 2026 MDR IVDR EU AI Act European Health Data Space (EHDS) Pathways to Market Access and Reimbursement The fragmented reimbursement landscape across the EU remains a significant challenge for founders. However, country-specific blueprints, such as the German DiGA program, are providing a crucial model for market access. Case Study: The German DiGA Program The German Digital Healthcare Act (DVG) created a fast-track process for digital health applications (DiGAs) to become reimbursable by Germany's statutory health insurance. This is a critical blueprint for founders to study and emulate. A DiGA must be a medical device in a lower risk class, be primarily based on digital technologies, and demonstrate a "positive care effect" through scientific studies. The fast-track process allows for a provisional listing in the DiGA directory for 12 months, during which the developer can provide a hypothesis and evaluation concept to prove the positive care effect. The nationwide rollout of e-prescriptions for DiGAs, which has been delayed and is now expected at the earliest in 2026, is a key milestone that will standardise and accelerate the process of patient access. The German DiGA program is a critical blueprint for the pan-European market because it offers a clear, fast-track process for reimbursement by focusing on a "positive care effect". Its success demonstrates how a country-specific market access pathway can be operationalized and scaled. For founders, securing a DiGA listing validates their solution's value and provides a repeatable path to revenue, which significantly de-risks the company for future investment or acquisition. For the wider ecosystem, it is a crucial step toward standardizing reimbursement and creating a more predictable market, potentially influencing other EU member states. The German DiGA Fast-Track Process: Key Steps and Requirements Step 1. Application 2. Evidence Submission 3. Provisional Listing 4. Price Negotiation 5. e-Prescription Launch Go-to-Market and Sales Strategy A founder’s go-to-market strategy must be customer-centric and value-driven. This involves moving from a generic sales approach to one that builds strong, trust-based relationships with diverse stakeholders, including clinicians, administrators, and payers. The most effective strategy is to demonstrate tangible value and return on investment (ROI). Founders must use case studies and data-driven evidence to show how their solutions improve patient outcomes, enhance operational efficiency, and deliver cost savings. Case studies should highlight key metrics and quantifiable results to help potential customers visualise the impact of the solution on their own organisation, making it easier for them to justify the investment. Priorities for Investors: A Data-Driven Investment Thesis for 2026 The "Selective Scale" Funding Model The investment landscape has evolved from a period of "exuberance to a more grounded reality," where capital has tightened and rising costs have made financing challenging. As a result, investors are now prioritising profitability and stable growth over aggressive expansion, focusing on companies with "proven business models". The new investment thesis is built on three pillars: a focus on clinically validated datasets, clear reimbursement pathways, and robust, defensible AI pipelines. Strategic Investment Hotspots Despite a cooler global venture market, digital health funding in Europe experienced a strong surge in the first quarter of 2025, reaching $2.1 Billion. This renewed confidence is channeling investment into specific high-growth areas: AI-First Platforms: These are the primary magnet for investment, with AI-deploying startups raising $701 million in 2025 alone. Investors are willing to pay premiums for proprietary algorithms and scalable platforms, with revenue multiples of 6-8x reported for these assets. Value-Based Care Enablers: Startups that assist provider organisations in succeeding under risk-based care models, by providing tools for predictive risk stratification, real-time outcomes tracking, or payment reconciliation, are gaining significant attention. FemTech: This is a rising niche market with significant growth potential. Despite receiving only a small fraction of current digital health investment, the market is gaining attention, particularly in areas like women's cardiovascular and immunology research. Valuation and Exit Landscape The market is experiencing a cautious but discernible rebound, with average revenue multiples for HealthTech companies generally ranging from 4-6x, and a Q1 2025 average of 4.8x. For profitable companies, Enterprise Value (EV) to EBITDA multiples are observed in the 10-14x range as of mid-2025, a slight increase from the previous year. A key focus for investors is the defensibility of a company's intellectual property and its ability to ethically leverage data. The EHDS, by creating a common framework for health data, will increase the value of companies that can navigate its strict security and interoperability requirements to ethically monetise data for research, innovation, and personalised medicine. This focus on "data monetisation capabilities" is a key factor in attracting premium valuations. M&A is the dominant exit pathway, driven by both strategic and financial buyers. The rise of PE activity and the increase in larger, more strategic deals indicate a robust and maturing exit environment for high-quality assets. HealthTech Valuation Multiples & Investment Hotspots (Mid-2025) Valuation Metric EV / Revenue EV / EBITDA Top Investment Hotspots AI-First Solutions Value-Based Care Enablers FemTech Priorities for Buyers and Sellers: Positioning for a Strategic Transaction Drivers of M&A Activity For both buyers and sellers, the M&A landscape in 2026 is defined by a strategic imperative. For buyers, acquisitions are the fastest path to optimise their portfolios, gain rapid access to new technologies and talent, and achieve economies of scale in a highly fragmented market.This is particularly true for large biopharma companies looking to fill pipeline gaps and offset patent cliffs by acquiring early- to mid-stage innovators. For sellers, an M&A event is the primary path to a premium exit. The market consolidation trend means that for many founders, especially those of startups, a strategic transaction is the key alternative to risking obsolescence in a maturing market where larger entities are acquiring niche players to create more comprehensive offerings. The Buyer's Playbook: Targeting Strategic Innovation Buyers must prioritise the acquisition of companies with proven AI solutions, robust data monetization capabilities, and a clear alignment with value-based care models. These areas consistently command premium multiples and offer significant long-term strategic value. Buyers must be prepared for increased competition for high-quality assets, necessitating swift action and a clear understanding of the target's unique value proposition. Flexible deal structures, such as earn-outs, royalties, and joint ventures, are becoming more common and are crucial for bridging valuation gaps and mitigating risk. The Seller's Playbook: The Path to a Premium Exit The key to a premium exit for sellers lies in positioning their company as a high-quality asset by demonstrating tangible outcomes and a clear path to profitability from the outset. A primary value driver for sellers is achieving regulatory readiness and compliance, which serves a paradoxical function in the European market. While regulatory compliance is often perceived as a costly and time-consuming burden, successfully navigating the complexities of the MDR, IVDR, the EU AI Act, and the EHDS effectively de-risks a company for potential acquirers. This regulatory "passport" demonstrates not only safety and legitimacy but also the potential for continent-wide scaling and data interoperability, which are high-value strategic goals for buyers.This turns a compliance cost into a strategic value driver that can justify premium multiples in a transaction. The market is seeing a growing preference for alternative deal structures. Sellers should be open to negotiating earn outs, royalties and joint ventures to align interests and secure deals in a dynamic financial environment. Co-development partnerships are also emerging as a way to mitigate regulatory and reimbursement risks in digital health. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #MedTech #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us at MedTech and HealthTech industry events   Digital Health Rewired > 18-19th March 2025 > Birmingham, UK  NHS ConfedExpo   >  11-12th June 2025 > Manchester, UK  HLTH Europe >  16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate >  25th June 2025, London, UK  HIMSS AI in Healthcare  >  10-11th July 2025, New York, USA Bits & Pretzels >  29th Sept-1st Oct 2025, Munich, Germany   World Health Summit 2025  >  October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit >  October 16th 2025, London, UK  HLTH USA 2025 >  October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025  >  October 27th-30th 2025, Riyadh, Saudi Arabia Web Summit 2025 >  10th-13th November 2025, Lisbon, Portugal   MEDICA 2025 >  November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

Nelson Advisors invited to Judge the 'HealthInvestor Power List 2025' Awards #HIPowerList25 HealthInvestor Power List 2025 Awards Nelson Advisors Partner  Lloyd Price  has been invited to Judge the 'HealthInvestor Power List 2025 Awards' recognising the most effective, inspiring and influential leaders in Health and Social Care https://healthinvestorpowerlist.com 'Our name change from HealthInvestor Power 50 to HealthInvestor Power List reflects our commitment to inclusivity and broader recognition within the industry, showcasing a diverse and comprehensive range of leaders and innovators.' With new categories and independently judged by a panel of industry experts, we can better acknowledge the dynamic and evolving landscape of our industry, celebrating excellence in a way that is both inclusive and representative of health investment. For nearly 15 years, we have celebrated the most effective, inspiring and influential leaders in health and social care. In 2025, we’re recognising the ever-evolving landscape of our industry with new categories, independently judged by a panel of experts, to celebrate excellence within the sector. HealthInvestor Power List 2025 Awards Nexus Media Group The Awards are hosted by Nexus Media Group, a leading B2B publishing and events company for the health, social care, seniors housing, education, early years and property sectors. Nexus Media Group is a publishing and events company, which focuses on the health, education, early-years and property sectors. Our range of established media titles and sector-leading events provide market intelligence and business connections, underpinned by a long-standing commitment to editorial excellence.   Established in 2004, our London-based team of journalists and sector experts provide insight and introductions to complex marketplaces. https://nexusmediagroup.co.uk Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #MedTech #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us at MedTech and HealthTech industry events   Digital Health Rewired > 18-19th March 2025 > Birmingham, UK  NHS ConfedExpo   >  11-12th June 2025 > Manchester, UK  HLTH Europe >  16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate >  25th June 2025, London, UK  HIMSS AI in Healthcare  >  10-11th July 2025, New York, USA Bits & Pretzels >  29th Sept-1st Oct 2025, Munich, Germany   World Health Summit 2025  >  October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit >  October 16th 2025, London, UK  HLTH USA 2025 >  October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 >  10th-13th November 2025, Lisbon, Portugal   MEDICA 2025 >  November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada HealthInvestor PowerList Awards 2025 >  3rd December 2025, London, UK  Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

Strategic MedTech Buyers Going Global: A New Era of Cross-Border M&A Executive Summary The global MedTech sector is entering a new era of mergers and acquisitions (M&A) characterised by a pronounced shift from broad portfolio expansion to highly selective, technology-driven acquisitions. While the broader healthcare M&A landscape experienced a decline in deal volume and value in 2024, the MedTech sub-sector demonstrated remarkable resilience. This report highlights that a period of market resurgence is underway, driven by a strategic focus on a smaller number of high-value deals. The primary catalysts for this activity are the urgent pursuit of innovations in artificial intelligence (AI), advanced surgical solutions, and digital health, as well as the imperative of market consolidation and global expansion. This new M&A environment is not without its challenges. Dealmakers must navigate a complex web of regulatory disparities between key markets like the U.S. and Europe, heightened geopolitical scrutiny, and the intricate process of post-merger integration (PMI). Despite these hurdles, strategic buyers like Johnson & Johnson, Stryker, and Boston Scientific are demonstrating how targeted acquisitions can accelerate growth, fill portfolio gaps, and create new business segments. The outlook for 2025 remains optimistic, with sustained momentum expected to be fuelled by improving economic conditions and the continued demand for transformative technologies. This report concludes with actionable recommendations for both acquirers and target companies, underscoring the increasing importance of specialised partners, such as MedTech Contract Research Organisations (CROs), in navigating this dynamic landscape. The New Era of MedTech M&A: A Global Market Resurgence The MedTech M&A market has demonstrated a clear and significant rebound, signaling a new, more disciplined era for strategic dealmaking. This sector's performance in late 2024 and early 2025 stands in stark contrast to the broader trends observed in the healthcare industry, which saw a decline in both deal volume and value. Understanding this divergence is key to appreciating the unique drivers of MedTech M&A today. Contextualising the MedTech Rebound MedTech M&A activity is on a definitive upward trajectory. According to J.P. Morgan, MedTech companies announced 305 M&A transactions in 2024, the second-highest count in the past decade, just behind the 2021 peak. A closer look at the data reveals that this momentum accelerated significantly in the latter half of 2024 and into 2025. In Q1 2025, the upfront value of MedTech deals surged to approximately $9.2 Billion, a dramatic jump from the $2.7 Billion recorded in Q4 2024, despite a slight dip in transaction volume from 62 to 57 deals. This MedTech-specific data offers a crucial point of contrast with the broader healthcare M&A landscape. In 2024, the overall healthcare sector experienced a decline in deal volume and value, falling approximately 13% and 19%, respectively, compared to 2023. The MedTech sub-sector's resilience in the face of these headwinds is attributable to its strong underlying fundamentals. Strategic buyers and private equity firms are increasingly attracted to the sector's defensive characteristics, predictable cash flows, and robust growth prospects, particularly in areas like AI-driven diagnostics, wearables, and advanced surgical technologies. Defining the "New Era": The Shift from Volume to Value The primary characteristic of the current MedTech M&A landscape is a clear focus on fewer, yet larger and more strategic, acquisitions. This marks a fundamental departure from the previous periods of broad asset aggregation. The dramatic increase in the median upfront payment, which rose from just $14 Million in Q4 2024 to $250 Million in Q1 2025, provides tangible evidence of this shift. This trend indicates a market where buyers are exercising greater discipline and are less willing to pursue a wide range of smaller assets. Instead, they are concentrating their capital on singular, high-value investments with a high degree of confidence. This pattern suggests a mature market where dealmakers are seeking to acquire mature companies with deeper product pipelines and established commercial traction, rather than a speculative rush into early-stage ventures. For example, a single deal, Johnson & Johnson's $13.1 Billion acquisition of Shockwave Medical, accounted for 23% of the total annual M&A investment in 2024. This kind of transaction confirms that leading companies are pursuing large, strategic deals that align with core growth priorities, a trend that is expected to continue throughout 2025. Strategic Drivers Behind Cross-Border MedTech Acquisitions The decision to pursue cross-border M&A in the MedTech sector is driven by a complex interplay of technological, market, and financial factors. These drivers motivate companies to look beyond their domestic borders in a quest for a competitive advantage. The Pursuit of Innovation and Portfolio Gap-Filling The primary catalyst for MedTech M&A is the urgent need to acquire innovative technologies that can revolutionize healthcare delivery and outcomes. Companies are specifically targeting firms specialising in cutting-edge areas such as AI-driven diagnostics, remote patient monitoring, and advanced surgical technologies. The acquisition of these technologies is not merely about adding a new product to a catalog; it is about securing a position in a future where reimbursement models increasingly emphasise real-world data and improved patient outcomes. A clear trend is the acquisition of firms for their embedded, FDA-cleared AI functionality and data analytics capabilities. Stryker's acquisition of Inari Medical is a prime example of this strategy. While the deal expanded Stryker's footprint in cardiovascular care, a core driver was the integration of Inari's proprietary thrombectomy devices, which generate real-time procedural and outcomes data. This transaction aligns with Stryker's broader strategy of building a portfolio of procedural intelligence and AI-assisted technologies. The acquisition of AI assets is now a direct response to the need for data-driven solutions that can streamline clinical workflows and support new reimbursement models. This innovation-focused approach often manifests as a "string-of-pearls" strategy, where large strategic buyers make a steady stream of smaller, targeted acquisitions to fill specific portfolio gaps. For instance, Medtronic's purchase of Nanovis' nano-surface technology was a strategic move to incorporate advanced solutions into its next-generation spinal fusion devices. Similarly, Boston Scientific has pursued multiple deals, such as its acquisitions of Bolt Medical and SoniVie, to expand its portfolio in niche, high-growth specialties like peripheral vascular intervention. Market Consolidation and Global Reach The global MedTech market remains highly fragmented, with a large number of small and medium-sized companies, particularly in Europe. M&A offers a direct and efficient path to consolidation, allowing larger entities to achieve critical economies of scale and streamline operations. This market consolidation creates a "one-stop-shop" for healthcare providers, simplifying procurement processes and strengthening the bargaining power of the remaining major manufacturers. Cross-border acquisitions are also a fundamental strategy for expanding geographic reach and gaining access to new markets. While U.S. companies dominate as both acquirers and targets, they are increasingly seeking foreign firms, particularly in regions like Asia Pacific. The motivation extends beyond market entry; companies are also acquiring targets to gain access to skilled labor, economical production, and high-quality R&D capabilities and infrastructure. This global pursuit allows multinational firms to build diversified supply chains and tap into a broader talent pool. Economic and Financial Tailwinds The M&A landscape is also being shaped by shifting economic and financial factors. The anticipation of a more permissive regulatory environment and potential deregulation in the U.S. under a new administration is a significant catalyst for dealmaking. This potential for a less aggressive antitrust stance could accelerate deal values and volumes over the coming year. A key feature of the new era is the rise of more flexible, risk-shared deal structures. In response to volatile biotech valuations and economic uncertainty, acquirers are increasingly leveraging alternative deal structures such as earn-outs, royalties, and joint ventures. These structures offer a way to mitigate risk by tying additional payments to the achievement of specific, measurable objectives, such as regulatory milestones or commercial success. The persistent trend of low upfront payments since 2015, which reached a low of 8% of total deal value in 2024, reflects a long-term shift toward more conservative financial arrangements. Case Studies in Strategic Cross-Border M&A An analysis of recent high-profile acquisitions provides a tangible demonstration of the strategic motivations driving MedTech M&A today. Three leading players, Johnson & Johnson, Stryker, and Boston Scientific, offer compelling examples of this new, disciplined approach. Johnson & Johnson's Strategic Expansion in Cardiovascular Care Johnson & Johnson's MedTech strategy is to acquire businesses that immediately contribute to top-line growth and margin accretion. A core focus of this strategy has been the cardiovascular care market, a high-growth area with significant unmet needs. J&J has invested over $32 Billion in this space, with notable acquisitions including Abiomed and Shockwave Medical. The company's acquisition of Shockwave Medical for $13.1 Billion in 2024 exemplifies this singular, high-value approach. The deal provided J&J with a device that uses shockwaves to treat calcified plaque in heart vessels, addressing a critical need in cardiovascular intervention. The rationale for the acquisition was supported by strong quantitative data; Shockwave had reported a 49% year-over-year revenue increase in 2023, and J&J expects it to become its thirteenth business with annual sales exceeding $1 Billion. This transaction demonstrates a clear focus on acquiring a market leader with proven commercial traction to fuel immediate and long-term growth. Stryker's Innovation-Driven Approach Stryker has actively pursued an M&A strategy to sustain its growth at the "high end of MedTech" by integrating advanced technologies. The company completed seven deals in 2024, all of which were "tuck-in" acquisitions that fit within its existing business units. This approach is driven by a desire to build or buy technologies that can be integrated into broader care platforms and enhance the company’s product pipeline. The company's $4.9 Billion acquisition of Inari Medical is a flagship example of this strategy. The deal was a strategic move to expand into the fast-growing peripheral vascular segment, but its deeper value was in the integration of Inari's AI-assisted technology, which generates real-time procedural and outcomes data.This acquisition builds on Stryker's other AI-focused deals, such as the 2024 purchase of care.ai , and signals a clear commitment to acquiring procedural intelligence that aligns with the future of data-driven healthcare. Boston Scientific's Portfolio Diversification Boston Scientific’s M&A strategy is centred on achieving "category leadership" and expanding into "high-growth markets and adjacencies" that complement its existing portfolio. The company's approach is long-term and multi-pronged, often involving early-stage venture capital investments to de-risk promising technologies before a full acquisition. This allows the company to fill portfolio gaps without overpaying. The acquisitions of Axonics, Inc. and Silk Road Medical, Inc. illustrate this strategic focus. The acquisition of Axonics added differentiated devices for urinary and bowel dysfunction, strengthening Boston Scientific's urology portfolio. The Silk Road deal brought in a new approach to stroke prevention, further diversifying the company’s cardiovascular offerings. These transactions demonstrate a strategy of strengthening and diversifying the company’s core business units through targeted acquisitions, rather than pursuing broad-based asset aggregation. Notable Strategic MedTech Acquisitions (2024-2025) Acquirer Target Deal Value Date Strategic Rationale Stryker Inari Medical $4.9Bn Feb 2025 Expand into cardiovascular care and integrate AI-assisted procedural intelligence. Johnson & Johnson Shockwave Medical $13.1Bn May 2024 Strengthen leadership in cardiovascular intervention with a high-growth, high-margin asset. Zimmer Biomet Monogram Technologies N/A N/A Expand surgical robotics portfolio with an AI-driven, autonomous joint replacement platform. Medtronic Nanovis N/A N/A Integrate nano-surface technology to accelerate bone growth on spinal implants. Boston Scientific Axonics N/A 2024 Add differentiated devices to the urology portfolio to treat urinary and bowel dysfunction. Boston Scientific SoniVie Ltd $540M H1 2025 Expand interventional medical device portfolio in high-growth, niche specialties. Thermo Fisher Scientific Solventum’s purification & filtration business $4.1Bn 2025 Strategic acquisition to expand capabilities and fill portfolio gaps. Navigating the Complexities of Cross-Border Deals The pursuit of strategic targets in a global market introduces significant complexities that extend beyond financial valuation and due diligence. Regulatory, legal, and cultural hurdles present major risks that require sophisticated planning and execution. Regulatory and Geopolitical Hurdles The MedTech regulatory landscape varies significantly between major jurisdictions, creating a key challenge for cross-border deals. In the U.S., the Food and Drug Administration (FDA) provides a centralised and generally predictable regulatory pathway, and the agency has actively tried to make the U.S. an attractive market for new devices. By contrast, the European Union's Medical Device Regulation (MDR), introduced in 2021, has created a more complex and stringent regulatory environment. The MDR requires more clinical data, which has increased costs and extended time-to-market for medical devices, making the EU a less appealing entry point for some innovative technologies. Dealmakers must develop a nuanced, jurisdiction-specific strategy to navigate this regulatory dichotomy In addition to regulatory approval, cross-border deals face heightened geopolitical and legal scrutiny. Governments around the world are increasingly implementing stricter controls on foreign investment to protect national security interests, especially for sensitive technologies like AI that have dual commercial and military applications. Furthermore, acquiring a foreign entity can subject the target to additional compliance requirements, such as U.S. anti-corruption laws like the FCPA, which can add complexity and risk to the transaction. Comparative Analysis of US vs. European MedTech M&A Feature United States Europe Primary Regulatory Authority FDA (Centralised) EU Medical Device Regulation (EU MDR) Approval Process Predictable, though rigorous Stricter, with increased clinical data requirements and longer timelines Deal Structure Purchase price adjustments (PPA) are universal "Lock box" structures are more common Earn-out Metrics Revenue-based earn-outs are more prevalent EBIT/EBITDA is the preferred metric Liability Caps Typically lower (10% or less) due to widespread R&W insurance Typically higher (25% to 50%) Dispute Resolution Litigation is the default method Arbitration is much more common, especially in cross-border deals Profitability Generally higher operating margins due to lucrative market access Generally lower operating margins; market is more fragmented The Post-Merger Integration Imperative The success of any M&A transaction hinges on effective post-merger integration (PMI), a process that is particularly complex in the MedTech sector. Operational and IT integration is a significant hurdle, as it involves merging clinical and administrative systems while ensuring uninterrupted patient care and maintaining regulatory compliance. A fumbled IT integration can lead to severe consequences, including disrupted patient care, data loss, and regulatory non-compliance. The challenges are compounded by the fact that many healthcare entities use notoriously customised Electronic Health Record (EHR) systems that are difficult to merge. To mitigate these risks, experts recommend that PMI planning begin during the due diligence phase, with a phased integration approach to minimise disruption. Beyond the technical aspects, cultural and talent integration present some of the most unpredictable challenges. The value of a MedTech company often lies not just in its tangible assets but in its talent and the entrepreneurial culture that fuels its innovation engine. While cultural friction between national and organisational cultures can pose a risk to integration, studies have found that foreign ownership can nonetheless enhance the profitability of acquired firms. To address these risks, strategic acquirers are adopting decentralised operating models to help maintain the distinctive culture and entrepreneurial spirit of acquired firms. For example, Johnson & Johnson has transitioned to a decentralised structure, moving 32,000 associates into individual business units, and Stryker’s decentralized operating model is cited as a key to its success. Outlook and Strategic Recommendations for MedTech Leaders The strategic focus and cautious optimism that defined the MedTech M&A market in late 2024 are expected to persist and even accelerate in 2025. This momentum, combined with a sustained focus on technological innovation, will shape the future of the sector. Future Trends and the Road Ahead The outlook for the second half of 2025 is for sustained M&A growth, driven by improving macroeconomic conditions, continued portfolio gap-filling, and the relentless pursuit of innovation.The focus on AI, digital health, and advanced surgical technologies will remain paramount, with companies that possess embedded, FDA-cleared AI functionality becoming prime acquisition targets.This is a direct consequence of the shift towards outcomes-based reimbursement models, where solutions that incorporate real-world data are becoming central to product differentiation. The increasing importance of emerging markets will also become a more prominent trend. Acquirers are not just seeking market access but are also targeting these regions to acquire skilled labor, economical production, and R&D capabilities to supplement their domestic operations. This reflects a more sophisticated cross-border strategy focused on building diversified, global footprints. Actionable Recommendations for a New Era In this new era of selective, high-value dealmaking, both acquirers and target companies must adapt their strategies to maximise value and mitigate risk. For acquirers, the shift to high-value deals necessitates a more rigorous and comprehensive diligence process. The analysis indicates that strategic buyers should prioritise early-stage diligence on technology, legal, and intellectual property (IP) assets to uncover potential risks and liabilities. Furthermore, developing a robust, pre-deal PMI strategy that addresses operational, IT, and cultural integration challenges is essential for unlocking a deal's anticipated synergies. For target companies, the path to a successful exit has become more focused. To attract strategic buyers and secure higher valuations and upfront payments, companies should concentrate on building a strong, defensible technology portfolio, especially one with embedded AI and data capabilities, and achieving proven commercial traction. A critical, final consideration for all dealmakers is the increasing role of specialized partners in the MedTech M&A ecosystem. MedTech Contract Research Organisations (CROs) are emerging as key enablers of cross-border transactions, providing the necessary expertise to navigate complex regulatory frameworks, clinical trials, and market access hurdles. These specialised partners can de-risk a foreign target and streamline the post-merger integration process, making them an indispensable component of a successful M&A strategy. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #MedTech #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us at MedTech and HealthTech industry events   Digital Health Rewired > 18-19th March 2025 > Birmingham, UK  NHS ConfedExpo   >  11-12th June 2025 > Manchester, UK  HLTH Europe >  16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate >  25th June 2025, London, UK  HIMSS AI in Healthcare  >  10-11th July 2025, New York, USA Bits & Pretzels >  29th Sept-1st Oct 2025, Munich, Germany   World Health Summit 2025  >  October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit >  October 16th 2025, London, UK  HLTH USA 2025 >  October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025 > October 27th-30th 2025, Riyadh, Saudi Arabia Web Summit 2025 >  10th-13th November 2025, Lisbon, Portugal   MEDICA 2025 >  November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

Nelson Advisors Partner Lloyd Price invited to Judge the 'Digital Health Hub Foundation: Digital Health Awards 2025' at HLTH Event Digital Health Hub Foundation: Digital Health Awards 2025 Nelson Advisors Partner Lloyd Price invited to Judge the 'Digital Health Hub Foundation: Digital Health Awards 2025' at HLTH Event in Las Vegas in October Some past winners include ŌURA, Overjet, Healthy.io, Outset Medical and HeartFlow, Inc. This year’s sponsors include Genentech, Cooley and many venture capital firms and independent foundations. Every year, the awards have drawn extraordinary interest from the global digital health community, with over 1,000 companies applying—including industry leaders such as Suggestic AI, BioAge Labs, and RadAI —competing for top honors across our Best in Class and Rising Star tracks. The Digital Health Hub Foundation Awards @ HLTH spotlight the most innovative health tech companies transforming healthcare through technology. In 2025, we’re back with innovation-targeted categories, recognising the companies making the biggest impact. Each year, the competition attracts groundbreaking companies from around the world, with only the most impactful advancing to the final stage. Join us on this journey to explore new innovations and spotlight the most impactful companies transforming digital health. https://www.digitalhealthhub.org/awards/2025/digital-health-awards Digital Health Hub Foundation Awards 2024 Digital Health Hub Foundation Awards 2024 SAN FRANCISCO, August 18, 2025 - The Digital Health Hub Foundation announced that submissions are now closed for the 7th Annual 2025 Digital Health Hub Foundation Awards, the world’s leading digital health awards program, held each year at HLTH in Las Vegas on October 20, 2025. Some past winners include ŌURA, Overjet, Healthy.io, Outset Medical and HeartFlow, Inc. This year’s sponsors include Genentech, Cooley and many venture capital firms and independent foundations. Every year, the awards have drawn extraordinary interest from the global digital health community, with over 1,000 companies applying—including industry leaders such as Suggestic AI, BioAge Labs, and RadAI —competing for top honours across our Best in Class and Rising Star tracks. Our distinguished panel of judges, featuring top names from healthcare, AI, venture capital, and innovation, will soon begin the rigorous evaluation process to determine the quarterfinalists. In addition, the Awards Pavilion @ HLTH, the largest independent booth at the show, is already 85% sold out. With prime visibility in a high-traffic location, the Awards Pavilion is expected to fully sell out within the next 10 days, making it one of the most sought-after spaces for showcasing innovation. Digital Health Awards 2025' at HLTH Event Nelson Advisors > MedTech and Healthcare Technology M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech and MedTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech#HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands HIMSS AI in Healthcare > 10-11th July 2025, New York, USA World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany

The Automated Patient: The Future of Patient Engagement and Patient Self Management in the Next 5 Years Executive Summary The healthcare industry is on the cusp of a profound transformation, shifting from a traditional model of patient engagement to an increasingly automated, self-directed paradigm. Patient engagement, a cornerstone of value-based care, has historically relied on a collaborative, human-centric partnership between patients and their care teams. However, this model faces inherent limitations in scalability due to administrative burdens, staffing shortages, and the increasing complexity of chronic disease management. In response, a new era of patient automation is emerging, leveraging advanced technologies to streamline patient interactions and empower individuals to manage their health with minimal friction. This report defines patient automation as the application of technologies such as artificial intelligence (AI), machine learning (ML), and the Internet of Things (IoT) to autonomously handle routine administrative and clinical tasks. This transition is not a replacement for human care but rather a strategic reallocation of human resources toward complex, empathetic tasks. The shift is propelled by powerful technological innovations, economic pressures to reduce costs and improve efficiency, and a growing consumer demand for seamless, digital experiences. Market forecasts underscore this trend, with the AI in healthcare market projected to grow at a remarkable compound annual growth rate (CAGR) of 38.62% from 2025 to 2030, far outpacing the broader medical automation market. While patient automation promises substantial benefits, including enhanced efficiency for providers, improved health outcomes for patients and expanded access to care, its implementation is not without significant hurdles. The report details critical challenges related to data privacy, ethical considerations such as algorithmic bias, and the complex task of integrating new technologies with outdated legacy systems. Success over the next five years will hinge on a collective commitment from all stakeholders, providers, patients, developers, and regulators, to address these barriers proactively. The path forward requires a balanced approach that leverages technology to its full potential while safeguarding the human-centered principles of care, ensuring a future that is not only automated and efficient but also equitable and trustworthy. The Paradigm Shift: From Patient Engagement to Patient Automation The Foundational Concept of Patient Engagement Patient engagement is a core tenet of modern healthcare, rooted in the philosophy that empowering individuals to take an active role in their own care leads to better health outcomes and a more effective healthcare system. This model is fundamentally a partnership, where patients and healthcare professionals collaborate on treatment plans, share information, and work together toward shared health goals. This approach is considered vital for value-based care, as it helps close care gaps and drives action through timely, personalised outreach. Traditional patient engagement is built on several key pillars. It involves proactive, human-led communication to build trust and tailor messages using clinical and demographic data. This communication can occur through various channels, including SMS, voice, and email, to connect with patients on their terms. For individuals with long-term conditions, engagement means finding out more about their condition, learning new skills to manage their health, and working in close partnership with their care team. This collaborative effort is shown to have many positive effects, including improved outcomes for patients who are actively involved in their own care. Patient engagement platforms are designed to support this model by simplifying tasks like appointment scheduling, coordinating referrals, and delivering personalised education and reminders. The success of this model is evidenced by high engagement rates, with some platforms reporting over 90% engagement through mobile-first outreach. The Rise of Patient Automation Patient automation represents the next stage in this evolution. It is defined as the application of advanced technologies, such as AI and robotic process automation (RPA), to streamline and autonomously manage patient interactions and administrative tasks. This shift is a direct response to the operational challenges that limit the scalability of traditional, human-led engagement, including insufficient communication, staff shortages, and administrative burdens that lead to burnout and long wait times. The objective of patient automation is to transform patient interactions across multiple platforms, automating routine tasks like appointment scheduling, rescheduling, and cancellations, as well as handling customer service requests. By using natural language processing (NLP), these solutions can provide an empathetic, human-like customer service experience with 24/7 availability and multilingual support.Beyond administrative functions, automation extends to clinical workflows by providing automated appointment reminders, which can reduce no-shows and optimise clinic efficiency. It also streamlines patient intake by digitising forms and automatically entering data into electronic health records (EHRs), which minimises errors and reduces the time staff spend on manual data entry. The move from engagement to automation is a strategic response to the problem of scaling patient-centric care. The traditional engagement model, while effective, is labor-intensive and its reach is limited by the capacity of healthcare staff. As the demand for care grows, particularly for chronic conditions, a more efficient solution is required. Patient automation provides a pathway to "personalise at scale". By using AI-driven messaging and automated workflows, healthcare providers can maintain a consistent, high-quality, and personal connection with a larger population without a corresponding increase in manual effort. The transition is therefore not a rejection of patient engagement's goals but rather a technological advancement designed to achieve them more efficiently and on a broader scale. The central goal of patient self-management, empowering individuals to take control of their health, remains constant, but the means of achieving it are evolving from a human-driven partnership to a technology-facilitated, self-service model. Drivers and Market Dynamics (2025-2030) Technological Catalysts and Innovations The transition to patient automation is propelled by a synergy of groundbreaking technologies. At the forefront are artificial intelligence and machine learning, which serve as the primary engines for this transformation. AI applications in healthcare are multifaceted, ranging from clinical decision support systems that enhance diagnostic accuracy to predictive analytics that forecast health risks. For example, AI-driven imaging tools can analyse medical images with greater precision, leading to quicker and more accurate diagnoses in radiology and pathology. AI chatbots and virtual assistants provide patients with round-the-clock support, answering common questions and reminding them to take medication, which frees up healthcare workers to focus on more complex cases. The Internet of Things (IoT) and wearable technology are equally critical to this shift. These devices are the physical manifestation of patient automation, enabling continuous, real-time data collection outside of traditional clinical settings. For patients with chronic diseases like diabetes, hypertension, and cardiovascular disorders, devices such as continuous glucose monitors (CGMs), smartwatches with ECG capabilities, and wearable blood pressure monitors provide a constant stream of clinically relevant data. This continuous monitoring enables proactive interventions, such as adjusting medication before a situation worsens or preventing hospitalisations. The power of patient automation does not reside in any single technology but in their seamless integration. Wearable devices collect the data, which is then transmitted to a cloud platform. AI and ML algorithms analyse this vast dataset to identify subtle patterns that a human might miss, providing predictive insights and generating personalised alerts.This closed-loop system, from data collection and analysis to actionable feedback, is what truly defines the new era of patient self-management. Economic and Operational Imperatives Beyond the technological push, powerful economic and operational forces are driving the rapid adoption of patient automation. The global healthcare industry faces a severe shortage of skilled workers, with a projected deficit of 10 million health professionals by 2030. This is compounded by high levels of administrative burden and staff burnout. Automation offers a critical solution by handling repetitive tasks, such as scheduling, billing, and data entry, which allows clinical staff to reallocate their time to more valuable patient interactions. By reducing the strain on manual processes, AI systems can improve staff productivity and wellness, and even minimise errors caused by exhaustion. The financial benefits of automation are substantial. Research indicates that wider AI adoption could save the U.S. healthcare system an estimated $200 billion to $360 billion annually. These savings come from streamlining administrative workflows, optimising resource allocation, and improving patient flow. For example, automating patient intake can reduce registration times by 50%, while automating claims processing can minimise denials and improve cash flow for providers. Organisations that fail to embrace this transformation risk being left behind, as younger, digitally native patients increasingly seek out providers who offer a more modern, tech-enabled experience. Adopting these technologies is therefore not just about solving today's problems but about positioning an organisation for long-term survival and growth, effectively "future proofing" its operations. Market Forecasts and Projections (2025-2030) The financial outlook for patient automation technologies is robust, with several key market segments demonstrating high growth potential over the next five years. The medical automation market, which includes technologies ranging from surgical robots to software, is projected to grow from an estimated $52.09 billion in 2024 to $88.11 billion by 2030, a CAGR of 9.26%. The broader digital health market, which encompasses mHealth apps, telemedicine, and wearable devices, is set for even more explosive growth. It is projected to increase from $427.24 billion in 2025 to $1.5 trillion by 2032, exhibiting a CAGR of 19.7%. However, the most telling trend is the rapid expansion of the AI in healthcare market. This segment, which powers many of the solutions discussed, is projected to reach $187.69 billion by 2030, growing at a remarkable CAGR of 38.62% from its 2024 valuation of $26.57 billion. This data highlights that the primary driver of value creation in medical automation is no longer in hardware-heavy systems but in the intelligent software and analytics that empower patient self-management. This dynamic is critical for strategic planners and investors seeking to capitalise on the next wave of healthcare innovation. Market Segment 2024 Market Size (USD Billion) 2030 Forecast (USD Billion) CAGR (2025-2030) Medical Automation 52.09 88.11 9.26% Digital Health 376.68 (2024) 1,500.69 (2032) 19.7% AI in Healthcare 26.57 187.69 38.62% Impact on the Healthcare Ecosystem Impact on Patients The shift to patient automation offers a powerful suite of benefits for patients, but it also introduces new risks that must be carefully managed. On the positive side, automation empowers patients to take greater control of their health. Patients can leverage self-service capabilities to schedule appointments, view test results, and receive timely reminders, which fosters a more active and participatory environment. For those managing chronic conditions, automation enables a higher quality of life by providing tools to track progress, ensure medication adherence, and receive personalised feedback in real-time. Case studies show that patients using telehealth and remote patient monitoring (RPM) platforms have been able to safely manage complex conditions like chronic heart failure and COVID-19 from the comfort of their homes, preventing hospitalisations and maintaining their independence. However, this transition is not universally beneficial. A significant challenge is the "digital divide," where segments of the population may lack the digital literacy, consistent internet access, or financial resources to fully participate in an automated care model. Older adults or those in underserved communities may be left behind. Furthermore, while automated tools can be empathetic, they risk eroding the human connection that many patients value with their care providers. A Pew Research survey found that a majority of U.S. adults are uncomfortable with AI being used to diagnose and treat them, with a significant number concerned about the technology being implemented too quickly. This highlights a fundamental need to build patient trust and ensure a balance between technological efficiency and the human element of care. Impact on Providers and Health Systems For providers and health systems, patient automation promises to be a solution to many long-standing operational and clinical challenges. By automating routine administrative tasks like patient intake, billing, and claims processing, health systems can achieve substantial operational efficiencies. This frees up staff from monotonous, time-consuming workflows, allowing them to focus on more strategic initiatives and direct patient care. For example, AI-assisted voice technology can reduce the burden of clinical documentation for nurses, giving them more time and energy to focus on their patients. Clinically, automation offers a path toward proactive, rather than reactive, care. By continuously monitoring patient data from wearable devices, health systems can identify potential health issues before they become critical, thereby preventing complications and reducing hospital readmissions. The use of AI-driven clinical decision support systems also enhances diagnostic accuracy and helps providers formulate more personalised and effective treatment plans. The comparative benefits of a human-centric engagement model versus a technology-driven automation model are stark, particularly in terms of scalability and efficiency. While both aim to improve patient outcomes, automation enables these benefits to be delivered consistently and on a mass scale, without the constraints of a finite human workforce. Feature Patient Engagement Model Patient Automation Model Primary Mechanism Human-led partnership and personalized communication to empower patients to manage their health. Technology-driven workflows and AI-based systems that enable patients to autonomously manage their health. Communication Style Personalised, empathetic outreach tailored to a patient's terms, often human-initiated. Automated, scalable messaging that uses AI to adapt to each patient, providing 24/7 availability. Operational Efficiency Limited by staff capacity, leading to burdens like long wait times and administrative overload. Reduces manual effort by automating tasks like scheduling, intake, and billing, which improves staff productivity. Clinical Focus Supports self-management through education, action planning, and collaborative goal setting. Enables proactive care through real-time data monitoring and predictive analytics for early intervention. Scalability Difficult to scale due to reliance on human labor and manual processes. Highly scalable, allowing for consistent, high-quality communication and care coordination for a large patient population. Key Benefits Higher patient trust, better communication, and improved outcomes for engaged individuals. Substantial cost savings, reduced staff burnout, fewer no-shows, and smoother patient journeys. 4. Navigating Barriers and Challenges Ethical and Social Implications The full promise of patient automation cannot be realized without a concerted effort to address its significant ethical and social challenges. A primary concern is data privacy and security, as these systems handle vast quantities of sensitive patient information. The increased exchange of data across interconnected networks, particularly with non-HIPAA-regulated apps like fitness trackers and symptom checkers, expands the potential for unauthorised access and misuse. Patient digital health information is highly valuable and can be used for profiling, targeted advertising, or even discrimination. The success of new initiatives, such as the CMS HealthTech Initiative, will hinge on a "shared commitment" to uphold strong security and privacy standards, especially given the current lack of a formal enforcement mechanism for data shared outside the traditional healthcare system. Another critical issue is algorithmic bias and fairness. AI models are trained on historical data, and if that data is limited or reflects existing healthcare disparities, the AI's recommendations may perpetuate or even amplify biases against certain demographic groups. This could lead to unequal or inadequate care. For patient and provider trust, it is essential that AI systems are transparent and explainable, so that both parties can understand how the technology arrived at its conclusions. Finally, a core ethical challenge is balancing the efficiency of automation with the inherent need for human empathy and connection in healthcare. While AI can handle routine tasks, final clinical decisions must remain with trained professionals, and the technology should serve to augment, not replace, the doctor-patient relationship. Ethical and Social Consideration Description Implications for Patients and Providers Data Privacy & Security The collection and exchange of sensitive patient data across diverse networks and apps, including those not governed by HIPAA, creates an expanded risk surface for unauthorised access. Patients: Fear of data misuse, commodification, and discrimination, which can erode trust and lead to reluctance to adopt digital health technologies. Providers: Increased compliance burden and reputational risk in the event of a data breach or legal challenges. Bias and Fairness AI models trained on limited or unrepresentative data may produce biased results, leading to unequal treatment recommendations for different demographic groups. Patients: Risk of receiving inadequate or inappropriate care, which can exacerbate existing health disparities. Providers: Responsibility to ensure that the AI tools they use are validated for a diverse patient population and do not introduce unintended biases into clinical workflows. Transparency & Explainability AI systems often operate as "black boxes," making it difficult for providers and patients to understand how a recommendation or decision was made. Patients: Lack of understanding can lead to mistrust in the technology and reluctance to follow its advice. Providers: Inability to explain an AI's rationale to a patient can undermine the doctor-patient relationship and create liability risks. Loss of Human Touch As automation handles more patient interactions, there is a risk that patients may feel less connected to their care providers, reducing their sense of being seen as a person rather than a data point. Patients: May feel like a number, potentially leading to worse health outcomes and reduced patient satisfaction. Providers: A fundamental need to re-skill staff to focus on complex, empathetic interactions that cannot be automated. Regulatory and Compliance Hurdles The rapid pace of technological innovation often outstrips the development of a corresponding regulatory framework, creating a climate of uncertainty and risk. This presents a significant hurdle for the widespread adoption of patient automation. In the U.S., the FDA has begun to release draft guidance for the use of AI in medical devices, focusing on a multi-step process that checks for bias, data trustworthiness, and cybersecurity. This is a crucial step, but the dynamic nature of AI, where algorithms can change over time, poses a challenge for traditional regulatory approval processes. A major regulatory gap exists in the governance of patient data collected by consumer-facing apps and wearables, which often falls outside the protective scope of HIPAA. While initiatives like the CMS HealthTech Initiative are designed to facilitate data exchange, their voluntary nature and lack of formal enforcement mean that the privacy and security of a patient's health information ultimately depend on the follow-through of participating entities, not on mandatory regulations. This policy-technology gap is a critical risk factor. The technology exists to share data seamlessly, but without a clear, enforceable framework, patient trust is fragile, and the risk of data commodification and misuse remains high. The AMA has raised concerns about this lack of safeguards, noting that a patient's digital medical records are far more valuable than their financial information on the open market and can be used for discrimination. Technical and Integration Challenges The success of patient automation hinges on a robust technical foundation, yet many healthcare organizations are still grappling with outdated infrastructure. The most significant technical barrier is the struggle to integrate new AI tools with legacy EHR systems. These systems often suffer from poor data quality, messy data entry, and siloed information, which can make it difficult for AI to get the clean, well-connected data it needs to function accurately. The multi-billion dollar, and highly problematic, EHR rollout at the VA is a cautionary tale, demonstrating that flawed foundational systems can lead to patient safety risks and increase staff burnout, even with significant investment. The central technical obstacle to patient automation is not the technology itself but the underlying data environment. Simply "plugging in" a new AI tool is insufficient if the data feeding it is inaccurate or fragmented. The high costs and patient safety issues observed in large-scale EHR updates illustrate that a significant portion of the strategic effort must be directed toward modernising and standardising IT infrastructure first.Without a stable and interoperable data environment, AI implementation risks not only failure but also causing direct harm to both patients and providers. Real-World Applications and Strategic Insights Case Studies and Pilot Programs The concepts of patient automation are already being translated into tangible, real-world applications across the healthcare spectrum. In the clinical and operational realm, health systems are piloting AI-assisted voice technology to reduce the administrative burden of clinical documentation for nurses, allowing them more time for direct patient care. Baptist Health South Florida has successfully used an AI tool to analyse EHR data and identify high-risk patient groups, enabling doctors to provide better, more proactive care. For chronic disease management, telehealth and remote patient monitoring platforms have demonstrated proven value. Case studies from Health Recovery Solutions show that patients with conditions ranging from COVID-19 to heart failure have used these platforms to monitor their vitals, receive medication reminders, and access educational content from home, which helped them recover safely and avoid readmissions. The FCC's Connected Care Pilot Program is a clear example of a governmental effort to leverage these technologies to expand care access, with a specific focus on low-income and veteran populations. Similarly, initiatives like Jacaranda Health's SMS platform in Africa show how automated two-way communication can reach and support underserved communities. Key Players and Innovation Hubs The development of patient automation is being led by a diverse group of stakeholders, from major corporations to academic research institutions. Industry leaders include multinational conglomerates like Siemens, Honeywell, GE HealthCare, and Oracle, which are integrating AI and IoT into their diagnostic and hospital management systems. Alongside them are specialised health tech companies like Biofourmis, which focuses on AI-driven in-home care, and Simbo AI, which provides AI-assisted voice solutions for administrative tasks. Academic and research groups are crucial for advancing the science behind these technologies and ensuring their ethical application. Prominent institutions include Duke AI Health, which is focused on foundational research and training the next generation of data scientists for medicine. Cedars-Sinai's Artificial Intelligence in Medicine Research Center designs ethically-vetted AI solutions for major diseases. Other key players include the Self-Management Resource Center, a leader in evidence-based self-management programs, and the American Medical Association (AMA), which is actively working on health data privacy frameworks to guide the future of digital health. Future Outlook and Recommendations The transition from patient engagement to patient automation is an inevitable and beneficial evolution for the healthcare industry. The evidence indicates that over the next five years, AI, IoT, and other advanced technologies will increasingly enable a more efficient, proactive, and patient-centric care model. To navigate this transformation successfully, a strategic approach is required from all stakeholders. For Healthcare Providers and Health Systems: Prioritise Foundational Investments: Before deploying complex AI, invest in modernizing legacy IT infrastructure and ensuring high-quality, interoperable data systems. The operational and patient safety risks of failing to do so are significant. Start Small to Build Trust: Begin by automating low-risk, high-volume administrative tasks like scheduling, billing, and patient intake. This can demonstrate a clear return on investment (ROI), build staff confidence, and allow for a gradual, managed transition. Focus on the Human Element: Leverage automation to free up clinicians' time, but reallocate that time to enhance the empathetic, complex patient interactions that cannot be automated. This preserves the essential human connection in care. For Patients and Consumers: Become Digitally Literate: Actively seek out information on digital health tools and their proper use. Understand the benefits and limitations of these technologies to participate effectively in your own care. Demand Transparency and Control: When using digital health apps and services, be aware of what data is being collected and with whom it is being shared. Seek out providers who offer clear consent mechanisms and who are transparent about their data usage policies. For Technology Developers and Regulators: Build Trust by Design: Create AI systems that are transparent and explainable, minimizing bias and ensuring fair outcomes for all patient demographics. This is a critical step for building the long-term trust required for widespread adoption. Forge Clear Regulatory Frameworks: Regulators must work proactively to develop clear, enforceable guidelines that govern data privacy, security, and the clinical validation of new technologies. This will help close the policy-technology gap and provide a stable, trustworthy environment for innovation to thrive. In conclusion, the future of patient self-management is automated. The shift will be driven by a powerful confluence of technology and market pressures, leading to a more efficient and accessible healthcare system. However, the success of this transition over the next five years will be measured not just by its technological achievements, but by the collective ability to address the fundamental challenges of data privacy, ethical responsibility, and human centred design. The ultimate goal is to create a future where automation serves to empower patients and providers alike, leading to better health outcomes for everyone. Nelson Advisors > MedTech and Healthcare Technology M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech and MedTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech#HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nurses as the Primary Data Source: Fuelling the Next Generation of AI Models Redefining the Role of the Nurse in an AI-Augmented Future The integration of artificial intelligence (AI) into healthcare is not a question of if, but how. This report asserts that for AI to be implemented ethically and effectively, the nursing profession must be at the forefront of its development. Nurses are not merely the end-users of these technologies; they are the indispensable link between raw patient data and human-centered care. By shifting from a traditional technology-first approach to a collaborative, human-in-the-loop co-design model, healthcare organisations can unlock AI’s full potential. This strategic paradigm will be demonstrated as the key not only to enhancing operational efficiency and improving patient outcomes but also to directly addressing the pervasive issue of nurse burnout and fundamentally redefining the value of the nursing profession in the digital age. The Clinical Foundation of Healthcare AI: Why Nursing Expertise is Irreplaceable The intellectual and practical basis for the central thesis of this report rests on the premise that a nurse's clinical expertise is the essential ingredient for building AI systems that are both safe and effective. The nursing role moves far beyond a superficial understanding of bedside care to encompass a deep, continuous, and holistic cognitive function that AI is uniquely positioned to augment. Beyond the Bedside: The Unique Domain Knowledge of Nursing The most impactful AI tools in healthcare are not generalised applications but highly specialised systems designed to address the unique pain points and workflows of specific clinical disciplines. For the nursing profession, this involves functionalities such as patient education, care coordination, and holistic assessments. Unlike a general physician's focus on diagnosis and treatment, a nurse's expertise centres on the continuous management of a patient's physical, emotional, and social needs. This nuanced perspective is critical to the development of AI tools that are truly useful. The analysis of these specialised applications reveals a foundational truth: AI's true value in healthcare is a function of its specialisation, which is a direct consequence of its integration with domain-specific knowledge. A generalised "healthcare AI" is therefore insufficient; the most effective AI systems will be nursing-specific because the data and use cases differ fundamentally from those of other clinicians. This implies that successful AI development must not begin with a technical concept but with a deep understanding of the unique clinical logic and workflows that nurses manage on a daily basis. Unpacking the "Hidden Complexities": The Nuanced and Holistic Nature of Nursing Practice While AI excels at data processing and automation, it cannot replicate the "soft elements" of nursing care, such as genuine empathy, emotional support, and adaptability to unforeseen changes in a patient's condition.These qualities represent the high-value, non-quantifiable aspects of the profession that are least susceptible to automation. For example, a seemingly simple task like inserting an intravenous line involves a complex, multi-layered assessment of the patient's skin color, hydration status, and circulatory system, factors that are inherently difficult to quantify and are not easily captured by an algorithm. This nuanced perspective is the very source of innovation. The Mount Sinai Health System offers a clear example: the idea for a new AI tool to prevent pressure injuries, or bed sores, originated not from a data scientist but from a clinical nurse. Her firsthand clinical observations of a persistent problem became the blueprint for a fully realised predictive software product. This demonstrates that the nurse's ability to identify a clinical challenge that a data scientist might miss is the first and most critical step in the AI development lifecycle. The Mount Sinai example is not simply a case study of a successful tool; it is a clear blueprint for a nurse-led innovation pipeline, where the profession's deep understanding of "hidden complexities" serves as the foundational knowledge for building effective AI solutions. Nurses as the Primary Data Source: Fuelling the Next Generation of AI Models Beyond their role as innovators, nurses are the primary generators and curators of the data that fuels AI. Detailed nursing notes and observations captured in electronic medical records (EMRs) are critical for powering next-generation AI tools. For instance, Natural Language Processing (NLP) algorithms are being trained to analyse nursing triage notes to identify predictors for which Emergency Department patients are likely to be admitted to the hospital. This direct link between nursing documentation and AI's intelligence reinforces the central assertion of this report. Nurses are "strongly attuned to capturing the patient and nurse story through data". However, a key challenge exists: the data that AI models currently consume is an incomplete representation of the true nursing role. The "hidden complexities", the empathy, the subtle observations, the emotional support, are not easily documented in standardised charts. This creates a fundamental paradox in nursing data. The current datasets omit the most critical human-centric variables that define high-quality care. Consequently, the report concludes that for AI to be truly effective, the nursing role must expand beyond data generation to include shaping new data collection methods that capture these nuanced, holistic elements. Current Applications of AI: Transforming the Nursing Workflow AI is already actively augmenting the nursing profession across multiple domains, transforming daily workflows from reactive to proactive and from administrative to patient-focused. A detailed overview of these applications demonstrates how technology can serve as a strategic partner to the nursing profession. From Burden to Bedside: Automating Administrative and Repetitive Tasks A significant portion of a clinician's day, often more than two hours, is spent on tasks other than direct patient care. This administrative burden is a major contributor to nurse burnout. AI offers a clear and immediate solution by automating time-consuming and repetitive duties such as documentation, scheduling, data entry, and patient intake. Ambient AI and voice-enabled charting tools, for example, listen to what nurses say during care and automatically create notes, reducing the time spent on typing and paperwork. This is more than a simple efficiency gain; it is a direct value proposition that frees up valuable time for direct patient care, reaffirming the human centred aspect of the role. The causal relationship is explicit: by alleviating administrative burden, AI enables nurses to return to the core purpose of their profession, leading to improved patient interaction and care. Augmenting Clinical Judgment: AI-Powered Decision Support Systems and Predictive Analytics AI serves as a powerful partner in complex clinical decision-making. AI-powered Clinical Decision Support Systems (CDSS) are a prime example, using advanced analytics to process and interpret massive volumes of patient data from sources like electronic health records (EHRs), vital signs, and laboratory results. By identifying patterns in this data, these systems provide evidence-based recommendations, supporting nurses in making more informed decisions. One of the most impactful applications of this technology is in predictive analytics. AI algorithms can analyse real-time patient data to predict the risk of adverse events such as patient deterioration, falls, and the onset of sepsis up to 12 hours before clinical recognition. Similarly, AI-powered wearable devices provide continuous, real-time monitoring of patients' vitals, activity levels, and other physiological markers, alerting nurses to subtle changes that may be early warning signs. This predictive capacity fundamentally changes the nature of a nurse’s job from a reactive response to a proactive intervention. It is a powerful example of augmented intelligence, where the technology enhances the nurse’s cognitive capabilities, enabling timely and life-saving interventions that improve patient outcomes. Extending Care Beyond the Clinic: AI's Role in Remote Patient Monitoring and Engagement AI is expanding the scope of nursing beyond the traditional hospital walls. AI-enhanced remote patient monitoring (RPM) has become a critical tool for managing chronic care and reducing hospital readmissions by providing continuous, 24/7 oversight of patients from the comfort of their homes. This approach alleviates the burden of constant surveillance for nurses, allowing them to intervene only when significant deviations from a patient's baseline are detected. In addition, AI-powered chatbots and virtual assistants are being used to provide personalised reminders, educational content, and interactive check-ins, empowering patients to take a more active role in their care. This capability addresses the "bandwidth problem" that health systems face in maintaining patient engagement between visits. AI provides a scalable solution that fosters a sense of continuous connection and oversight. However, it is imperative that these AI-driven systems are paired with human oversight to ensure that empathy, clarity, and cultural competence are maintained. Application Specific Function Impact on Workflow Patient Benefit Administrative Automation Automates documentation, scheduling, and data entry. Reduces time on repetitive tasks, freeing nurses for direct patient care. Improved patient interaction, enhanced care quality, and reduced medical errors. Clinical Decision Support Systems Processes large datasets to provide evidence-based care recommendations. Augments clinical judgment, enabling more informed and timely decisions. Improved diagnostic accuracy, better treatment plans, and reduced complications. Predictive Analytics Analyzes real-time data to forecast patient trajectories and risks. Shifts the nursing role from reactive to proactive, enabling early intervention. Prevention of adverse events (e.g., falls, sepsis), reduced hospital admissions, and improved safety. Remote Patient Monitoring Uses wearables and sensors for continuous, real-time data analysis. Provides 24/7 oversight, allowing nurses to monitor patients from a distance. Reduced readmissions, effective chronic disease management, and a greater sense of security. Patient Engagement Tools Chatbots and virtual assistants offer personalized education and reminders. Scales the nurse's ability to engage with patients beyond clinical visits. Enhanced adherence to treatment plans, greater self-efficacy, and continuous support. A Framework for Nurse Led AI Co-design: The Imperative of Collaboration The most successful AI tools are those built not for nurses, but with them. A prescriptive framework is required to incorporate nursing expertise at every stage of the development lifecycle, ensuring a collaborative, interdisciplinary approach that elevates the nurse's role from a passive user to an active co-creator. The Strategic Imperative of Human Centred Design Human-centered design (HCD) is a process that prioritises understanding the end-users and ensuring that technology solutions fit smoothly into existing workflows. The user interface (UI) for AI tools in healthcare must be explainable, simple, and designed for collaboration, not control, to avoid pitfalls such as alert overload and "black box" decisions that fail to provide context for an AI's conclusion. This approach is not merely about a good user experience; it is a critical strategy for building trust. A failure to implement HCD principles will not just lead to a bad user experience; it will exacerbate the existing crisis of trust between nurses and their employers. The National Nurses United (NNU) survey, for instance, found that nurses already experience a similar problem with automated systems that generate inaccurate handoffs and assessments. In this environment, trust becomes the true key performance indicator (KPI) for healthcare AI, not just efficiency metrics or clicks. The UIs must be designed with "oh-oh" moments in mind—the instances where the AI gets something wrong—and must include failsafes that allow a nurse to override an AI's suggestion easily, thereby empowering professional judgment. From Idea to Implementation: Nurses' Role Across the AI Development Lifecycle To build trustworthy and effective AI, nurses must be involved at every stage of the development lifecycle, from the initial design through deployment and ongoing evaluation. Nurses have a professional responsibility to be knowledgeable about the data used to train AI models and to ensure transparency throughout the process. This necessitates interdisciplinary collaboration with data scientists, clinicians, and ethicists, which is crucial for creating innovative and ethically sound tools. The Mount Sinai case study provides a tangible blueprint for this co-design model. In that instance, a clinical nurse identified a specific problem—the prevention of pressure injuries, that had not been addressed by a technology solution. Her idea was collaboratively explored and transformed into a fully realised product by a team of internal data scientists and software engineers. This demonstrates that the most impactful AI tools originate from those who understand the problem most intimately, underscoring the necessity of nurse-led innovation. Development Stage Nurse's Essential Contribution 1. Problem Identification / Ideation Identifying a clinical challenge that can be solved with AI based on firsthand experience and deep domain knowledge. 2. Data Curation & Annotation Providing expert insight on what constitutes high-quality, relevant data; annotating data to capture complex clinical nuances and "hidden complexities." 3. Prototyping & Co-design Offering real-time feedback on user interface, workflow integration, and a system's explainability to ensure it fits into daily practice without disrupting human-centered care. 4. Testing & Validation Participating in pilot programs to test the AI's accuracy and reliability, providing critical feedback on its performance in real-world clinical situations. 5. Deployment & Evaluation Overseeing the safe rollout of the tool, educating other nurses on its appropriate use, and providing continuous feedback for ongoing improvements. 6. Policy & Governance Contributing to the development of ethical guidelines and institutional policies that govern the use of AI, ensuring they align with core nursing values. Navigating the Hurdles: Barriers to Nurse-AI Collaboration Despite the clear benefits of nurse-AI collaboration, several significant barriers hinder adoption. A balanced, objective analysis acknowledges and validates the concerns of the nursing profession, which are often rooted in social, political and technical challenges. A Crisis of Trust: Addressing Nurse Skepticism and Algorithmic Bias A major barrier to AI adoption is not technical, but social and political. A National Nurses United (NNU) survey found that 60% of nurses do not trust their employers to implement AI with patient safety as the first priority. Many nurses feel that AI is a tool used to undermine their clinical judgment and are unable to modify AI-generated assessments or categorisations. This creates a fundamental contradiction: technology developers and administrators often view AI as a solution to burnout and staffing shortages, while nurses view it as a means to justify unsafe staffing levels and erode their professional autonomy. This deep-seated distrust stems from a perception that AI is being deployed not to genuinely augment care but to serve organisational efficiency goals at the expense of patient safety. The success of AI implementation is therefore not just a matter of technology; it is a matter of leadership, transparency and a fundamental resolution of this core conflict of interest. Simply training nurses on new technology will fail if the underlying institutional culture does not prioritize nurse input and patient safety over short-term efficiency gains. The Technical and Ethical Chasm: The Challenges of Data Quality, Interoperability and Accountability The technical challenges in AI implementation are not merely engineering problems; they are ethical and professional dilemmas. AI requires large, high-quality, and standardised datasets to function effectively, but healthcare data often suffers from inconsistencies, incompleteness, and a lack of standardisation across different systems. This technical limitation can directly lead to algorithmic bias, where an AI system trained on biased data may perpetuate or even amplify existing health disparities. Furthermore, the "black box" nature of some advanced AI algorithms, which makes it difficult to understand how a decision was reached, erodes trust and poses a serious problem for professional accountability. In a field where decisions have life-or-death consequences, the inability to explain an AI-driven outcome is a direct challenge to the nurse's professional judgment and legal accountability. These issues highlight that nurses, with their patient-facing perspective and ethical obligations, are uniquely positioned to identify and mitigate these risks, ensuring that technology serves the principles of justice and fairness in healthcare. Barrier to Collaboration Proposed Solution A Crisis of Trust Foster transparency through clear communication about AI's purpose, benefits, and limitations; formalize nurse input in the design and deployment of tools to rebuild trust in leadership. Algorithmic Bias Involve nurses in data curation and testing to identify and mitigate biases; implement policies that prioritize equity and justice in AI development. Fear of Job Replacement Reframe AI as an augmentation, not a replacement; create new career pathways in nursing informatics and data science to show opportunities for professional growth. Data Quality Issues Invest in data governance frameworks and standardization initiatives; engage nurses in developing new methods for capturing nuanced, holistic data. Technical & Ethical Chasm Prioritize the development of explainable AI (XAI) models; create multidisciplinary governance committees to address issues of accountability and privacy. Lack of AI Literacy Integrate AI education into nursing curricula; offer continuous professional development opportunities on new technologies. A Strategic Roadmap for the Future: Preparing the Nursing Profession for an AI Integrated World The successful integration of AI requires a forward-looking, multi-pronged plan that prepares the future nursing workforce and empowers institutional leaders to navigate the challenges ahead. Reimagining Nursing Education: Preparing a Future-Ready Workforce The skills of the future will be knowledge-based, not task-based. To meet this demand, AI literacy is becoming a crucial competency in nursing education. Nursing curricula must move beyond traditional methods to incorporate training on AI. Innovative educational strategies include interactive simulations that use AI-enhanced robots or virtual reality to mimic real-world scenarios, allowing students to practice complex procedures like IV insertion in a risk-free environment. This hands-on, problem-based approach serves a dual function: it teaches a technical skill while simultaneously training nurses on how to interact with and trust AI systems. Other effective methods include using case studies, organising collaborative hackathons to solve nursing challenges, and hosting ethics discussion panels to critically evaluate the implications of AI. This integration is not a separate training module but an intrinsic part of modern nursing education, preparing students not just for a job, but for a new kind of profession. Empowering New Roles: The Rise of the Informatics Nurse and Data Scientist AI integration is a catalyst for professional evolution, not a threat to employment. As automation takes over routine tasks, new career pathways are emerging that require a unique blend of clinical and technical expertise. Nurses who develop skills in data analysis and machine learning can transition into roles such as informatics nurses and data scientists, bridging the gap between clinical practice and technological innovation. Furthermore, AI integration is creating new leadership roles for nurse managers, who are now responsible for leading the adoption of these technologies and managing their seamless integration into clinical workflows. This evolution frames AI as a tool that frees nurses to take on higher-level, more strategic responsibilities, thereby elevating the entire profession. Policy and Leadership Recommendations for Institutional Adoption The ultimate success of AI in a healthcare setting depends on institutional support, leadership commitment, and a proactive policy framework. Healthcare organisations must formally establish multidisciplinary AI governance committees that include nurses, managers, developers, and ethicists to evaluate and vet all AI tools before they are deployed. These committees should prioritise human-centred design principles to build trust and ensure that the AI's purpose is to augment, not undermine, the nursing profession. Nurse managers play a pivotal role in this process, as their strategic decisions can directly impact AI adoption within their teams and help overcome resistance to change by ensuring that AI-driven processes align with core nursing values and patient centred care. Conclusion: A Partnership for a Better Future The evidence presented in this report leads to a single, unequivocal conclusion: nurses hold the key to developing AI tools that are not only intelligent but also safe, effective, and ethical. The future of healthcare AI is not about a machine replacing a human, but about a symbiotic relationship where an intelligent tool works in concert with a compassionate professional. By freeing nurses from administrative burdens and augmenting their clinical judgment, AI can enhance their capacity to deliver the empathetic, human centred care that defines their profession. This report serves as a powerful call to action for institutional leaders to proactively engage with nurses as co-creators, ensuring that technology serves humanity in meaningful ways and that the core values of nursing - care, compassion and critical thinking, remain at the heart of healthcare innovation. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors invited to lead the 'HealthTech M&A and IPOs Panel' at the Global Health Exhibition 2025 in Riyadh, Saudi Arabia #GHE25 Nelson Advisors Partner Lloyd Price will lead the 'HealthTech M&A and IPOs Panel' at the Global Health Exhibition 2025 in Riyadh, Saudi Arabia. #GHE25 The Global Health Exhibition 2025 The Global Health Exhibition in Riyadh is a major event focused on healthcare innovation, investment, and transformation. It brings together global leaders from both the public and private sectors to discuss the future of healthcare. The exhibition features: Conferences: Including a Leaders Summit for high-level discussions, a Medical Excellence Forum, a Digital Health Forum, and a Venture Forum. Exhibition Floor: Showcasing the latest in healthcare technology, including digital health, AI, medical devices, and more. Networking: Opportunities for professionals, investors, and innovators to connect and explore partnerships. The event will take place from October 27-30, 2025, at the Riyadh Exhibition and Convention Center in Malham, Saudi Arabia. bringing together 1,000+ global presenters, 1,500+ exhibitors, and leading investors. The event capitalises on Saudi Arabia's dynamic healthcare market and its strategic position as a global investment hub. The event combines CME-accredited conferences, cutting-edge technology showcases, and exclusive investment forums, making it the definitive platform where healthcare innovation meets commercial opportunity in one of the world's most rapidly evolving markets. The Global Health Exhibition 2024 The Global Health Exhibition in Saudi Arabia is a major annual event that has quickly grown to become a prominent platform for the healthcare industry, both regionally and globally. Here's a look at its history and development: Origins and Purpose The Global Health Exhibition was launched in 2018 under the patronage of the Saudi Ministry of Health. Its creation was a direct response to Saudi Arabia's ambitious Vision 2030 plan, which includes a significant focus on transforming and modernizing the country's healthcare sector. The exhibition was established to provide a business platform for local and international healthcare companies to connect with the Saudi market and contribute to the Kingdom's healthcare goals. The event is organized by Informa Life Sciences Exhibitions, which also manages other major healthcare events like Arab Health. Key Milestones and Growth First Edition (2018): The inaugural exhibition took place from September 10-12, 2018, at the Riyadh International Convention and Exhibition Center. It aimed to provide a platform for 10,000 attendees to engage with over 500 exhibiting companies. The event also featured a multi-disciplinary congress with a focus on topics like Healthcare Transformation, Investment, and Innovation. Rapid Expansion: The exhibition has seen remarkable growth in subsequent years, reflecting the significant investment and focus on healthcare in Saudi Arabia. The event has expanded in size, attendance, and the number of participating countries. Post-Pandemic Transformation: The 2023 and 2024 editions of the Global Health Exhibition marked a new, transformative phase. The event has become a key forum for global collaboration and has witnessed the signing of numerous agreements and partnerships in areas like pharmaceuticals, biotechnology, and digital health. 2023 Edition: The 2023 exhibition, held from October 29-31, was themed "Invest in Health." It featured over 300 companies from 29 countries and focused on topics like preventive care, artificial intelligence, and biotechnology. 2024 Edition: The 2024 edition, held from October 21-23, was also a major success. It reportedly drew over 105,000 visitors, with 72% of attendees being international. The event saw announced investments and deals exceeding SAR 50 billion (Saudi Riyals), including significant projects in pharmaceutical manufacturing and digital transformation. It was held at the Riyadh International Convention and Exhibition Center in Malham. The Future: The exhibition continues to grow. The 8th edition is scheduled for October 27-30, 2025, and is expected to be the largest yet, with a continued focus on "Invest in Health" and attracting a high level of international participation. Core Focus Areas The Global Health Exhibition is more than just a trade show; it's a comprehensive platform for industry development. Key focus areas have included: Vision 2030: The exhibition is a cornerstone of Saudi Arabia's Health Sector Transformation Program, showcasing progress and attracting investments to achieve the goals of Vision 2030. Investment and Partnerships: It serves as a crucial hub for attracting foreign investment and fostering partnerships between public and private sector entities, both local and international. Innovation and Technology: The event highlights cutting-edge medical technologies, including AI, digital health solutions, and biotechnology, that are transforming the healthcare landscape. Knowledge Exchange: Through its various forums and conferences (such as the Leaders' Summit, Medical Excellence Forum, and Digital Health Forum), the exhibition provides a platform for experts and policymakers to share knowledge and discuss best practices. #GHE25 Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #MedTech#HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us at MedTech and HealthTech industry events   Digital Health Rewired >  18-19th March 2025 > Birmingham, UK   NHS ConfedExpo   >  11-12th June 2025 > Manchester, UK   HLTH Europe >  16-19th June 2025, Amsterdam, Netherlands HIMSS AI in Healthcare >  10-11th July 2025, New York, USA World Health Summit 2025   >  October 12-14th 2025, Berlin, Germany HLTH USA 2025 >  October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025 > October 27th-30th 2025, Riyadh, Saudi Arabia MEDICA 2025 >  November 11-14th 2025, Düsseldorf, Germany Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

Personal Health Large Language Models: HealthTech Trend to watch in 2026 Executive Summary The year 2026 is poised to be a pivotal year for the integration of artificial intelligence into healthcare, marked by the maturation of a new class of specialised systems known as Personal Health Large Language Models (PH-LLMs). These models represent a fundamental shift beyond general-purpose AI, moving from broad-based utility to domain-specific reliability. They are positioned to revolutionise the HealthTech landscape by acting as intelligent, reasoning engines that enhance both the patient journey and the efficiency of healthcare providers. The analysis reveals several key findings. First, the market for AI in healthcare is experiencing explosive and consistent growth, with varying projections consistently pointing toward a multi-hundred-billion-dollar valuation in the near term. This growth is buoyed by significant venture capital funding, with AI-enabled startups capturing the majority of investment dollars and commanding a substantial premium in deal size. Second, PH-LLMs are a new category of fine-tuned, customisable models engineered to understand and reason over diverse, multi-modal data, including wearable sensor outputs and electronic health records (EHRs). This technical foundation enables them to provide highly precise, personalised insights. Third, the primary value propositions for this technology are dual-pronged: they empower patients with proactive wellness coaching and symptom analysis while simultaneously addressing the critical issue of provider burnout through automated clinical documentation and workflow support. Fourth, the ecosystem is characterized by a dynamic interplay between established tech giants like Google, which are developing foundational models, and a robust field of well-funded startups like Hippocratic AI and Abridge, which are cornering high-return use cases. However, the path to widespread adoption is not without significant challenges. The report identifies critical risks related to data privacy, algorithmic bias, and accountability, which are being addressed by new regulatory frameworks from the U.S. Food and Drug Administration (FDA) and the European Union (EU). Controversial pilot programs, such as the one in Medicare, also underscore the high-stakes ethical and political debates surrounding AI's role in clinical decision-making. To navigate this complex environment, stakeholders must adopt a strategic approach. This includes focusing investment on specialized, compliant solutions, building AI systems with safety and transparency at their core, and implementing phased, well-governed integration plans within healthcare organisations. The Foundational Shift: Defining Personal Health Large Language Models (PH-LLMs) PH-LLMs vs. General-Purpose LLMs General-purpose Large Language Models (LLMs) are AI algorithms built on deep learning techniques and trained on vast, general datasets to understand and generate human-like text. These models, exemplified by tools like ChatGPT, are highly versatile and possess a broad range of pre-trained knowledge, making them useful for a wide array of applications. However, their inherent design presents significant drawbacks, particularly in a high-stakes domain like healthcare. Training and usage can be computationally expensive and time-consuming, and their outputs are prone to "hallucinations", the generation of incorrect or nonsensical information, which can lead to the spread of misinformation. Furthermore, due to their training on generalised data, these models lack domain-specific expertise, which makes them unreliable for specialised applications and can perpetuate ethical biases present in the human-produced data they were trained on. The healthcare market is responding to these limitations with the emergence of Personal Health Large Language Models (PH-LLMs), a new class of customisable LLMs fine-tuned on domain-specific data to provide precise and contextually aware responses for specialised applications. Google's PH-LLM, for example, is a version of Gemini that has been fine-tuned for text understanding and reasoning over numerical time-series personal health data from applications in sleep and fitness. This fine-tuning process allows PH-LLMs to achieve improved accuracy, reduced bias, and greater efficiency for niche tasks.The market is not simply adopting generic LLMs; it is rapidly moving toward highly specialised, fine-tuned PH-LLMs. The fundamental reason for this transition is the simple fact that the drawbacks of general LLMs, such as hallucinations and lack of domain expertise, are unacceptable in a clinical context where errors can have severe consequences. The development and validation of PH-LLMs against expert benchmarks is a direct market response to the demand for trust and reliability, transforming the technology from a convenient tool into a dependable medical instrument. This strategic transition explains why investors are channeling significant capital into companies with specialised AI solutions rather than just generic applications. The following table provides a comparative analysis to highlight the functional distinctions between these different types of AI systems. Feature Traditional Health Apps General-Purpose LLMs Personal Health LLMs (PH-LLMs) Data Scope Structured, manual input (e.g., calorie counting, step tracking) Vast, public, and unstructured datasets Specialised, multi-modal data (e.g., EHRs, wearables, biomarkers, text) Core Function Predefined functions, goal tracking, and progress visualisation Broad language understanding and generation for general queries Reasoning and inference over integrated data for personalised insights Key Advantage Simplicity and structured guidance Versatility and extensive general knowledge Domain-specific expertise, precision, and accuracy Drawback Lacks personalisation, siloed data, and limited interactivity Prone to hallucinations, lacks domain expertise, and high computational cost High data dependency, development cost, and regulatory complexity Primary Use Case Weight loss, fitness tracking, and medication reminders General health information, content creation, and administrative support Patient coaching, clinical decision support, and administrative automation The Distinction from Traditional Health Apps and Telemedicine Personal Health LLMs represent a new paradigm that is distinct from existing health apps and telemedicine platforms. A traditional health app is typically a structured, goal-oriented tool that provides predefined exercises, tracks progress, and offers information without a deep reasoning capability over complex, integrated data. Similarly, telemedicine is best understood as a delivery mechanism, the use of telecommunications technologies like videoconferencing to deliver remote clinical services—rather than a core intelligence layer. While telemedicine has helped overcome geographical barriers, it has also struggled to handle the high volume of patient inquiries, highlighting the need for an underlying layer of intelligence. PH-LLMs fill this gap by acting as a new intelligence layer that will permeate and fundamentally transform these existing systems. Unlike a generic app that can tell a user their average heart rate, a PH-LLM can integrate a user's heart rate trends, sleep data, and exercise logs from wearable sensors to generate a personalised, conversational insight about how a specific physical activity on a certain day may have impacted their physiological response. This is demonstrated by the PhysioLLM system, which integrates physiological data from wearables with contextual information to provide a comprehensive statistical analysis. A user study found that PhysioLLM was superior to both the Fitbit App and a generic LLM chatbot in facilitating a deeper, personalised understanding of health data and supporting actionable steps. The technology also acts as a critical intermediary in telemedicine, where it can automate initial patient assessments, summarise key medical information for clinicians, and even overcome language barriers to create a more cohesive care ecosystem.The future of HealthTech is a symbiotic relationship between data collection (wearables, EHRs), the delivery channel (telemedicine), and the reasoning engine (PH-LLM), which moves the user from a passive data viewer to an active participant in their health journey. The Technical and Functional Architecture of PH-LLMs The core of a Personal Health LLM's capability lies in its technical and functional architecture. These models are built on a foundation of multi-modal LLMs, such as Gemini, which are then fine-tuned on domain-specific data to achieve superior performance. This fine-tuning process incorporates the integration of analytical tools for specific domains, such as the ability to analyse nutritional intake for diabetic patient management or to interpret Photoplethysmography (PPG) signals from wearables for heart rate estimation. This technical foundation gives rise to a set of key capabilities that distinguish PH-LLMs: Data Integration: PH-LLMs can seamlessly ingest and reason over disparate data types, including unstructured text (notes, queries), numerical time-series data (from wearables), and structured data (EHRs, biomarkers).This multi-modal capability allows them to process a complete, real health data profile to answer queries. Personalised Insight Generation: By integrating and analysing this data, PH-LLMs can produce individualised recommendations and insights tailored to a user's specific health needs and goals. For instance, they can provide customised recipes that fit a client's nutritional needs and dietary restrictions. Reasoning and Inference: These models are not just conversational agents; they have the ability to perform complex calculations and make sophisticated inferences. They can suggest potential diagnoses and recommend treatment plans based on a patient's unique data set, distilling complex patient narratives into actionable insights. A study comparing the openCHA framework with GPT-4 in diabetic patient management found that the openCHA model, which integrated domain-specific knowledge, achieved a 92.1% accuracy rate, significantly outperforming GPT-4's 51.8% accuracy on the same questions. This demonstrates the power of fine-tuning and specialised architecture to exceed the performance of generic models. The Core of the Trend: Use Cases and Value Propositions Enhancing the Patient Journey: From Symptom Checking to Personalised Coaching Personal Health LLMs are creating a new category of proactive, preventative, and continuous care that blurs the lines between consumer-facing wellness and clinical medicine. One of the most immediate applications is in symptom analysis and triage, where conversational AI tools act as virtual assistants to conduct initial patient interviews, analyse symptoms, and suggest appropriate next steps. This helps reduce unnecessary emergency room visits and long wait times while offering a psychological benefit, as some studies suggest patients may feel more comfortable disclosing sensitive information to an AI than a human. A major value proposition lies in personalized wellness and coaching. By integrating data from wearable technologies and fitness trackers, PH-LLMs provide real-time feedback and suggest adaptive workout plans, personalised meal plans, and nutritional guidance that align with a user's goals and dietary habits.This approach moves the focus from reactive healthcare to proactive, continuous care, enabling the early detection of issues before they become acute conditions. PH-LLMs are also instrumental in chronic disease management and mental health support, with AI-powered chatbots and mood-tracking apps providing scalable, 24/7 support for emotional wellness and adherence to treatment plans. The ability to continuously analyse data from wearables and other sources allows for a shift away from reactive healthcare models and toward a continuous, data-driven approach that is more cost-effective and improves long-term outcomes for patients. Empowering the Healthcare Provider: From Clinical Workflows to Decision Support The most immediate and significant return on investment (ROI) for PH-LLMs is in streamlining provider workflows. The healthcare system is burdened by a substantial amount of administrative paperwork and data entry, with physicians reportedly spending nearly half of their time on non-clinical duties. This significant administrative burden is a major contributor to clinician burnout. LLMs directly address this problem through automated clinical documentation and ambient scribing. The technology can transcribe and summarise doctor-patient conversations in real time, automatically generating structured clinical notes, such as SOAP (Subjective, Objective, Assessment, Plan) notes, and flagging key information for inclusion in EHRs. This automation frees healthcare professionals to focus on direct patient interaction, which has been shown to reduce burnout and improve workflow efficiency. The high adoption rate of ambient scribes, hovering between 30% and 40% across physician groups, demonstrates that a clear business case for saving time and reducing administrative burden is a powerful catalyst for market penetration. This explains why funding is heavily concentrated in "non-clinical workflow" and "clinical workflow" solutions, which accounted for over half of all digital health funding in the first half of 2025. Beyond administrative tasks, LLMs are also becoming indispensable tools for clinical decision support and diagnostic assistance. By analysing vast amounts of medical literature, clinical notes, and patient records, these models can assist in diagnosing conditions, suggesting appropriate treatment plans, and providing evidence-based recommendations. A study comparing an open-source model (Llama) with a proprietary one (GPT-4) on complex clinical cases found that Llama made a correct diagnosis in 70% of cases, compared to GPT-4's 64% accuracy. This indicates the increasing maturity of this capability and its potential to optimise clinician performance and help reduce diagnostic errors. Additionally, LLMs are being used in medical education to simulate realistic patient interactions, allowing trainees to hone their communication and diagnostic skills in a safe environment. The Market Landscape: Growth and Investment Dynamics Market Size and Growth Projections The market for digital health and AI in healthcare is experiencing a period of explosive growth. While specific valuations vary across different reports, the consistent upward trajectory is undeniable. The global digital health market was valued at approximately $312.9 billion USD to $376.68 billion USD in 2024. This market is projected to reach between $1.5 trillion USD and $2.19 trillion USD by 2032–2034, representing a compound annual growth rate (CAGR) of 19.7% to 21.2% from 2025. Within this broader market, the AI in healthcare segment is growing at a disproportionately higher rate, indicating its significant influence on the entire sector. The AI in healthcare market, valued at $27.59 billion USD to $37.98 billion USD in 2024, is projected to grow at a staggering CAGR of 37% to 38.5% and reach over $600 billion USD by 2034. North America currently dominates the market, accounting for over 54% of revenue in 2024, with the U.S. alone valued at over $123.6 billion USD. However, the Asia-Pacific region is a quickly growing market, and South America is focusing on telehealth and remote patient monitoring, indicating a global proliferation of AI-driven solutions. Digital Health & AI Market Projections (2024-2034) Market Segment 2024 Value (USD) 2034 Forecast (USD) CAGR (2025-2034) Key Trend Digital Health $312.9B - $376.68B $1.5T - $2.19T 19.7% - 21.2% Rapid adoption of telehealth, AI-based tools, and wearables AI in Healthcare $27.59B - $37.98B $674.19B 37% - 38.5% Higher growth rate than broader market; significant investment in AI-enabled startups Investment Trends in HealthTech AI Venture capital funding for AI-enabled startups in the digital health sector is the primary financial driver of the current market momentum. In the first half of 2025, digital health VC funding reached $6.4 billion USD, with AI-enabled startups capturing the lion's share at 62% of the total, or $3.95 billion USD. These companies are commanding a significant premium; the average funding per round for an AI-enabled startup was $34.4 million USD, an 83% increase compared to the 18.8 million USD average for non-AI companies. This investment is increasingly concentrated in larger, later-stage rounds. In the first half of 2025, nine of the 11 "mega deals" (fundraises exceeding $100 million USD) went to AI-enabled startups. The top three funded value propositions were non-clinical workflow, clinical workflow, and data infrastructure, which together accounted for 55% of overall digital health funding in the first half of the year. This concentration of funding in workflow solutions underscores a clear business trend: investors are backing companies that solve immediate and painful problems, such as clinician burnout, which provide a clear and rapid ROI for healthcare systems. The Key Players: Companies, Models and Research The Titans of Tech Major technology companies are leveraging their vast resources to develop foundational LLMs for healthcare. Google, for example, is a key player, having developed models like Med-PaLM 2 and the Personal Health Large Language Model (PH-LLM). Its DeepMind division is active in pharmaceutical research and development, radiology, and unstructured data analysis. These companies are building powerful, foundational models with the intent of creating a platform for more specialised applications to be built upon. Innovating Startups A dynamic ecosystem of startups is demonstrating that the future of HealthTech is not in monolithic, single-purpose models but in specialised, high-value applications that integrate deeply into existing systems. Hippocratic AI is an example of this approach, with its Polaris 3.0 model, a suite of 22 LLMs with 4.2 trillion parameters. The model is designed for non-diagnostic clinical tasks and has achieved a high clinical accuracy rate of 99.38%. It boasts unique capabilities such as advanced emotional intelligence, robust audio handling for real-world phone calls, and deep integrations with major EHRs like Epic and Cerner. Another key player is Abridge, which provides an ambient AI clinical documentation tool that transforms patient-clinician conversations into structured clinical notes in real time. This tool integrates directly into EHR workflows and is designed to reduce physician burnout by automating note-taking and improving documentation quality. The investment focus on these specialised companies confirms that they are not directly competing with the tech giants; rather, they are carving out a defensible market position by creating solutions that solve a very specific pain point for providers and integrate seamlessly with existing hospital infrastructure. Other notable startups include Qure.ai for medical imaging, Biofourmis for remote patient monitoring, and Corti.ai for emergency response voice analysis. This market fragmentation suggests a future where no single company will dominate, but rather a collection of specialised, interoperable AI agents will manage different aspects of healthcare. Pioneering Research Institutions Academic and clinical research institutions are playing a vital role in pushing the boundaries of health LLMs. Researchers at the Boston Children's Hospital's Center for Health Information and Promotion (CHIP) are developing methods for rapid drug event detection, predictive pharmacology, and leveraging LLMs for public health initiatives. The Massachusetts Institute of Technology (MIT) focuses on developing AI technologies for the entire span of healthcare, from drug discovery to personalised care. Their research has also uncovered subtle but critical technical challenges, such as the finding that non-clinical information in patient messages, like typos or extra white space, can reduce the accuracy of medical recommendations. Stanford University's Human-Centred Artificial Intelligence (HAI) institute is leading the development of holistic evaluation frameworks, such as MedHELM, to assess medical LLMs on real-world clinical tasks rather than just standardised exam performance. This research community provides a critical foundation for validation and innovation. Critical Considerations: Risks, Challenges and Regulations Data Privacy and Security The widespread adoption of Personal Health LLMs presents significant data privacy and security risks. A major concern is the potential for data leakage, particularly from the "Bring Your Own LLM" (BYO-LLM) trend, where employees may input sensitive Protected Health Information (PHI) into public LLMs without proper oversight. Unlike traditional software, LLMs learn from the data they process, and sensitive information can be inadvertently stored and exposed. Even with anonymised data, sophisticated re-identification techniques can compromise patient privacy. To mitigate these risks, organisations must adopt a structured governance approach. This includes implementing a multi-pronged strategy with robust data anonymisation, using the principle of data minimisation (using only the minimum necessary data), and implementing strict access controls. For data in transit and at rest, strong encryption is essential. Encouraging the use of private, company-managed LLMs is a critical step to prevent data from being fed into external models.Additionally, healthcare organisations must conduct thorough due diligence on vendors and establish Business Associate Agreements (BAAs) to ensure compliance with privacy regulations like HIPAA. Algorithmic Bias and Ethical Concerns Algorithmic bias is an inherent risk in any machine learning model, as it reflects patterns and priorities encoded in the training data. When LLMs are trained on biased human-produced data, they can perpetuate harmful stereotypes and lead to algorithmic discrimination, which can exacerbate existing health disparities and disadvantage certain patient groups. These biases are a serious concern in clinical contexts, where they can lead to inaccurate diagnoses or inappropriate care recommendations. To address these issues, developers and deployers must focus on active bias mitigation. This involves using diverse and representative training data, implementing bias-mitigation benchmarks to identify gaps, and providing contextual transparency about the sources and processes behind the model's outputs. The development of a governance model that emphasises "fairness, transparency, trustworthiness, and accountability" is recommended to ensure the ethical use of AI in medicine. The Evolving Regulatory Landscape Regulatory bodies worldwide are working to establish frameworks to govern the safe and effective use of AI in healthcare. The FDA has issued final guidance on Predetermined Change Control Plans (PCCP), which allows manufacturers of AI-enabled medical devices to make specific, foreseeable software modifications without submitting a new marketing application for each update. This approach aims to streamline innovation while ensuring that changes remain within the intended use and are properly validated. There is also a proposed bill, the Healthy Technology Act of 2025, which could potentially allow qualified AI to prescribe drugs if it is authorised by state law and approved by federal provisions. In Europe, the AI Act, which entered into force in 2024, classifies AI systems intended for medical purposes as "high-risk". This classification subjects them to stringent requirements for risk mitigation, high-quality datasets, and human oversight. The EU's Product Liability Directive also updates liability rules for new technologies, ensuring that manufacturers can be held responsible for damages caused by a defective product, including those that learn or acquire new features after deployment. Pilot Programs: Case Studies in Progress The real-world application of AI is bringing these regulatory and ethical concerns to the forefront. A notable example is the controversial Medicare pilot program launched in six states that uses AI to make "prior authorisation" decisions, determining whether a procedure, such as spinal surgery, should be covered.Critics, including experts and union leaders, have likened the program to "AI death panels" and warn that it introduces the same issues seen in private insurance, where algorithms have been used to swiftly deny large batches of claims. A particularly contentious aspect is that the private AI firms are paid a share of the savings generated from the claims they reject, which critics argue creates a significant financial incentive to maximise denials and directly puts them at odds with clinicians. This case study highlights the complex ethical and political risks that arise when AI systems are used in high-stakes clinical and financial decision-making. Key Ethical and Regulatory Risks and Mitigation Strategies Risk Category Key Problem Mitigation Strategy Relevant Frameworks Data Privacy & Security Data leakage from BYO-LLM, re-identification risk of PHI Data anonymisation, strong encryption, private LLMs, BAAs HIPAA, GDPR, EU AI Act Algorithmic Bias Perpetuates harmful stereotypes and exacerbates health disparities Diverse training data, bias-mitigation benchmarks, ethical guidelines WHO AI principles, FDA oversight, EU AI Act Accountability & Trust "Black box" decisions, lack of transparency, inability to hold AI accountable Contextual transparency, human oversight, clear liability rules EU Product Liability Directive, FDA PCCP Regulatory Hurdles Rapid technological pace outstrips slow regulatory cycles Regulatory "sandboxes," continuous education, phased implementation FDA PCCP, EU AI Act, EHDS The 2026 Outlook: Future Trajectories and Strategic Recommendations Predictions for the HealthTech Ecosystem The future of HealthTech will be characterised by a continued and deepening convergence of technologies. PH-LLMs will become increasingly integrated with wearables, genomics, and telemedicine to create truly holistic, personalised health platforms.This synergy will enable a shift from episodic, reactive care to a proactive, predictive model. The growing maturity of open-source models, such as Llama and Me-LLaMA, which can already perform competitively with and in some cases even outperform proprietary models , is likely to accelerate innovation and reduce the reliance on a few large corporations. We can also expect to see a shift from single-purpose LLMs to complex, agentic AI systems that can autonomously handle decision-making and orchestrate entire workflows, from initial patient calls to EMR documentation. 6.2. Strategic Recommendations To navigate the dynamic landscape of 2026, stakeholders must adopt a clear strategy. For Investors: A focus should be placed on companies with a clear, validated business case and a strong value proposition, particularly those that offer a clear ROI for providers by automating clinical and non-clinical workflows. Additionally, investments should prioritise solutions that are building robust, HIPAA-compliant data infrastructure and governance frameworks from the ground up to mitigate legal and ethical risks. For Startups and Developers: The strategic imperative is to build "AI-native" solutions that integrate deeply with existing clinical workflows and systems, rather than simply offering a standalone tool. Prioritising safety, explainability, and compliance from the earliest stages of development will be crucial for gaining market trust and navigating the evolving regulatory environment. For Healthcare Systems and Providers: A phased implementation strategy is recommended, beginning with low-risk, high-value administrative tasks like ambient scribing and automated patient support before moving to more complex clinical decision support systems. A strong governance framework is essential to manage the risks of "Shadow IT" and ensure staff are properly trained on the ethical and secure use of PH-LLMs. Conclusion The rise of Personal Health Large Language Models is not merely a passing trend but a fundamental paradigm shift in the delivery and management of healthcare. By moving beyond the limitations of general-purpose AI and traditional apps, PH-LLMs are introducing a new layer of intelligence that can reason over a patient's entire health profile to provide personalized, proactive, and continuous care. While the market is experiencing explosive growth and attracting significant investment, the technology’s promise is inextricably linked to its ability to address complex ethical, regulatory, and social challenges. The controversies surrounding early pilot programs serve as a stark reminder of the high stakes involved. The future of HealthTech belongs to those who can master the delicate balance of driving innovation while building the most trusted, transparent, and accountable AI solutions for patients and providers alike. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech#HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands HIMSS AI in Healthcare > 10-11th July 2025, New York, USA World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025 > October 27th-30th 2025, Riyadh, Saudi Arabia MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Analysis of Venture Debt in the HealthTech Sector Executive Summary Venture debt has emerged as a critical and purpose-built financial instrument within the dynamic and capital-intensive health technology (healthtech) sector. This report provides an analysis of its strategic role, delineating its distinct strengths, inherent weaknesses, current opportunities and future trajectory. Venture debt is defined as a specialised loan for high-growth, venture-backed startups, uniquely underwritten based on a company's ability to raise future equity rather than its current cash flow or collateral. This model is exceptionally well-suited to the healthtech industry, where companies are often pre-revenue, have long R&D cycles, and hold their primary value in intellectual property rather than traditional assets. The key strengths of venture debt include its ability to provide non-dilutive capital, preserving founder and employee ownership while extending a company's cash runway to achieve critical milestones. It acts as an invaluable bridge between equity rounds, providing an "insurance policy" against market volatility and unforeseen challenges. Conversely, the instrument is not without its risks. The cost of venture debt can be high, compounded by interest rates, fees, and the dilutive effect of warrants. The fixed repayment schedule places significant pressure on cash flow, and restrictive covenants can limit a company's operational flexibility. Current opportunities for venture debt in healthtech are significant. The instrument can serve as "jet fuel" for commercialisation and market expansion, or as a crucial source of funding for capital-intensive R&D and clinical development. Real-world examples, such as Aledade's strategic use of debt to finance its growth, underscore its practical utility. The future of venture debt in this sector is particularly promising, driven by the surge in AI-enabled healthtech, which is creating a new class of companies with clearer paths to profitability, and the rise of specialized lenders with deep domain expertise. As the healthtech market matures and pivots toward a focus on durable, outcomes-driven business models, venture debt is poised to move from a niche financing option to an integral component of a sophisticated capital stack. The HealthTech Financing Ecosystem Defining Venture Debt Venture debt is a specialised financial product designed specifically for fast-growing, venture-backed startups. It serves as a complementary source of capital, often secured at the same time as or soon after a new equity raise, such as a Series A or Series B round. The primary purpose of this loan is to provide additional, non-dilutive capital to support growth and operations, helping a company extend its runway until the next funding event. Unlike traditional bank loans, which rely on a company's historical cash flow and collateral, the underwriting for venture debt focuses on the borrower's ability to raise additional capital to fuel growth and ultimately repay the debt. This unique underwriting model makes venture debt an attractive financing option for companies that are cash-burning and lack the consistent revenues or tangible assets required for conventional credit. A typical venture debt facility is structured with three main pricing components: an interest rate on the loan balance, an origination fee, and stock purchase warrants granted to the lender. These loans are usually short- to medium-term, with a repayment period of three to four years, and often include an initial 6- to 12-month interest-only (I/O) period to alleviate immediate cash flow pressure. The amount of venture debt available is generally calibrated to the size of the recent equity round, often ranging from 25% to 35% of the amount raised. This strategic ratio ensures that the company is not overburdened with debt that could create a "debt overhang" and complicate future fundraising efforts. The Distinctive Demands of the Healthtech Sector The healthtech and life sciences industries are characterised by unique financial and operational demands that set them apart from other sectors. Many of these companies, particularly in areas like biopharma and medical devices, are inherently capital-intensive, requiring substantial and prolonged investment to cover R&D, clinical development, and regulatory approval costs. For these startups, the time from inception to profitability can span many years, and consistent revenue streams are often absent during critical developmental phases.This reality makes traditional financing options, which depend on steady cash flow, largely unviable. Furthermore, the most valuable assets of a healthtech company are often intangible. Intellectual property (IP), such as patents, proprietary technologies, and trade secrets, constitutes the core value proposition for many of these ventures. This focus on intangible assets presents a challenge for lenders accustomed to securing loans with physical collateral like property or equipment. The unique lifecycle of a healthtech venture, with its long and unpredictable timelines to market, requires a financing strategy that can adapt to key value inflection points, which may not align with the typical, predictable cadence of venture capital fundraising rounds. Comparative Analysis of HealthTech Financing Options The decision to utilise venture debt is a strategic choice made within a broader financing ecosystem. To understand its true value, it is essential to compare it to the other funding options available to healthtech founders. Venture Debt vs. Venture Capital: Venture capital (VC) is an equity investment where investors provide capital in exchange for ownership stakes and, frequently, a board seat. VC returns are realised through a successful exit, such as an acquisition or an Initial Public Offering (IPO). While VC is a long-term investment that provides strategic guidance and a network of experts, it comes at the cost of significant equity dilution and a potential loss of control for founders. By contrast, venture debt is a loan that requires repayment with interest, but it preserves ownership for founders and employees, with warrants representing a comparatively small dilutive effect. Venture debt is a financial tool for short- to medium-term needs, whereas VC is an investment in the company's long-term vision. Venture Debt vs. Non-Dilutive Public Funding: Public grants from organisations like the National Institutes of Health (NIH) or the Biomedical Advanced Research and Development Authority (BARDA) are exceptionally attractive because they are non-repayable and non-dilutive, preserving 100% of a company's equity. These grants are particularly useful for funding early-stage R&D. However, they are highly competitive, come with a rigorous application and review process, and impose strict requirements and reporting obligations tied to specific projects or initiatives. In comparison, venture debt provides more flexibility in how the capital can be used to achieve a variety of business objectives. Venture Debt vs. Revenue/Royalty Financing: Revenue-based financing (RBF) and royalty financing are alternative non-dilutive options where a company receives capital in exchange for a percentage of its future revenue or royalties. Repayment schedules are flexible and fluctuate with income, aligning with the company's financial performance. These options are best suited for companies with existing, predictable revenue streams or a strong portfolio of royalty-generating IP. However, for startups in the R&D stage with no consistent revenues, these models are not viable. The synthesis of these comparisons reveals a fundamental role for venture debt in the healthtech capital stack. It occupies a critical middle ground, addressing a financing gap where traditional loans are inaccessible and other options are either strategically suboptimal or unavailable. The underwriting model, which prioritises a company's ability to attract future capital, and its use of IP as collateral, make it a purpose-built instrument for the unique challenges of the healthtech sector. It provides founders with a powerful lever to bridge critical phases of development without sacrificing the equity they have worked to build. Healthtech Financing Options - A Strategic Comparison Feature Venture Debt Venture Capital Public Grants (eg. NIH, BARDA) Revenue/Royalty Financing Dilution Minimal (via warrants) Significant (via equity) None None (in exchange for revenue share) Repayment Obligation Yes, with interest None None Yes, via percentage of revenue/royalty stream Use of Funds Flexible (growth, R&D, cash cushion) Broad (long-term growth, key hires, product dev) Restricted to specific R&D projects Flexible (growth, marketing) Collateral / Underwriting Future funding ability; IP, AR, equipment Growth potential, team, market opportunity Alignment with funder's mission; rigorous review Existing revenue stream or royalty-generating IP Stage of Applicability Early to later-stage (post-equity round) All stages (pre-revenue to later-stage) Primarily early-stage R&D Post-revenue or with valuable, licensed IP Overall Risk / Benefit Lower dilution, but with repayment burden and covenants High risk/high reward, but can lead to loss of control Non-dilutive, but highly competitive and restrictive Non-dilutive and flexible, but tied to revenue performance Strengths: The Strategic Advantages of Venture Debt Capital Preservation and Ownership Integrity The most compelling advantage of venture debt for healthtech founders is its ability to provide capital while maintaining the integrity of a company's ownership structure. By choosing venture debt, a company can secure significant funding without issuing new shares and diluting the equity of its founders, employees, and existing investors. This is a particularly powerful benefit when compared to a traditional equity round, which can dilute ownership by 20% or more. While venture debt facilities typically include a warrant component that gives the lender the option to purchase a small percentage of company shares in the future, the dilutive effect is minor, often representing less than 5% of the company's total ownership. This capital preservation allows founders and their teams to retain a much larger share of the eventual upside, aligning incentives for long-term value creation. Beyond financial ownership, venture debt also allows founders to maintain greater operational and strategic control. Unlike venture capital firms, which often require a board seat and have significant governance rights, venture debt lenders do not typically seek board representation or involvement in the day-to-day management of the business. The current board composition remains intact, preserving the autonomy of the founding team and existing investors. Operational Leverage and Milestone Achievement Venture debt is an exceptional tool for extending a company's cash runway, providing a crucial bridge between funding rounds. By providing three to nine months of additional operating capital, it buys a company the time it needs to achieve key milestones, which can significantly increase its valuation and bargaining power for the next equity raise. For healthtech companies, this is particularly vital for hitting value inflection points such as completing a clinical trial, securing FDA approval, or achieving a proof-of-concept. Instead of being forced into an expensive and dilutive bridge round to stay afloat, a company can use venture debt to strategically position itself for a more favourable future financing event. Furthermore, the capital raised through venture debt can be strategically deployed to accelerate a company's growth plan. Funds can be used for specific, high-impact initiatives such as hiring or bolstering a sales team, expanding marketing efforts, investing in R&D, or purchasing critical capital equipment to reach commercialisation. For a company like Aledade, which successfully used a growth capital term loan to help finance its continued growth, this provided a clear path to achieving its mission of delivering better care outcomes. Operational Flexibility and Capital Optimisation Venture debt provides an element of financial flexibility that is difficult to replicate with other funding sources. It can be used as a cash cushion or an "insurance policy" against unforeseen operational challenges, fundraising delays, or unexpected capital needs. A strategic time to secure a venture debt facility is when a company is financially strong, as this is when its creditworthiness and bargaining power are at their peak. By putting a facility in place with an extended "draw period," a company can have access to capital when it needs it most without having to draw on the loan immediately. From a capital optimisation perspective, venture debt can also reduce the average cost of a company's capital structure. In many cases, it is a far more cost-effective option than giving up a significant portion of a company's equity, especially when the company is scaling quickly and burning cash. Some venture investors themselves appreciate the role venture debt plays in reducing the cost of capitalising their portfolio companies, as it allows them to leverage their own equity and deploy it more efficiently. Signal Amplification and Investor Confidence The act of securing a venture debt facility serves as a powerful signal of a company's financial stability and growth potential. A lender's decision to provide a loan to a pre-revenue or cash-burning startup is a form of validation, demonstrating that a sophisticated financial institution has assessed the business and believes in its ability to raise follow-on capital. This can, in turn, make the company more attractive to future equity investors by signaling expanded liquidity and financial momentum. The fundamental value of venture debt is not in providing a standalone source of capital but in its ability to amplify the value of existing equity. The core strategic purpose is to use the loan to accelerate growth and hit milestones that justify a higher valuation for the next equity round. This creates a virtuous cycle: venture debt provides the "jet fuel" to extend runway and fund initiatives, which leads to a higher valuation, which in turn means the subsequent equity round is less dilutive. This reduces the overall cost of capital for the company while preserving the founder's ownership and control. The instrument's true power lies in its capacity to strategically position a company for a more successful and less dilutive future. Weaknesses: Mitigating the Risks and Challenges The True Cost of Capital: Beyond the Interest Rate While venture debt is often touted as a less expensive alternative to equity, the true cost of capital is multifaceted and must be carefully evaluated. The all-in cost of a venture debt facility includes more than just the interest rate, which typically falls between 7% and 12%, though this can vary significantly based on the lender's risk assessment. The cost also includes an upfront origination fee and the value of the stock purchase warrants granted to the lender. These warrants, which offer the lender equity upside, are a key feature of the venture debt model. The high-risk nature of lending to cash-burning startups means that venture debt interest rates are inherently higher than those for traditional bank loans. Companies in sectors with "binary risks," such as those tied to a single regulatory approval or an unproven technology, are often considered riskier borrowers and may face higher costs. Furthermore, since interest rates can be floating and tied to macroeconomic conditions, a high-interest-rate environment can increase the cost of servicing the debt and place significant strain on a company's cash flow. The Burden of Repayment and Default Risk A core difference between venture debt and equity is the fixed repayment obligation. Unlike equity financing, which does not need to be paid back, venture debt is a loan that must be repaid on a strict, predefined schedule, regardless of whether the company is profitable. This repayment schedule can create immense financial pressure, particularly for startups with irregular or non-existent revenue streams. For example, a pre-revenue life sciences company, or a SaaS company with a small, volatile customer base, might struggle to meet regular debt obligations. The risk of default is a major concern. Failure to make scheduled payments can lead to a default on the loan, which may trigger the "acceleration" of the entire outstanding balance, making the full amount immediately due. If a company is unable to pay, lenders may have the right to force the company into bankruptcy or liquidate its assets to recover their capital. Furthermore, a company with too much debt can face a "debt overhang" that makes it unappealing to new investors, as they may be reluctant to invest fresh equity that will simply be used to repay old debt. The Impact of Covenants and Collateral Venture debt is not a "no-strings-attached" form of financing. Lenders often include covenants in the loan agreement to mitigate their risk and protect their interests. These covenants are a set of rules that the borrower must follow, and breaching them can trigger a default, with severe consequences. While venture debt covenants are typically less restrictive than those found in traditional bank loans, they can still limit a company's operational and strategic flexibility, potentially hampering its growth. Common examples of covenants include financial metrics, such as a requirement to maintain a minimum cash balance or to achieve specific revenue or growth targets. Operational or restrictive covenants can place limits on a company's ability to take on new debt, issue dividends, sell major assets, or transfer intellectual property without the lender's consent. For a healthtech startup, the impact of these restrictions can be particularly acute, as they may limit a company's ability to make strategic pivots or invest in new R&D programs. Venture debt loans are generally secured by a company's assets. For life sciences and healthtech companies, the most significant assets are often their intellectual property rights. This means that the loan is secured by IP, which can present a complex negotiation point. The inherent tension of venture debt is that founders gain flexibility by avoiding dilution, but they do so at the cost of a fixed repayment obligation and the possibility of operational constraints imposed by covenants. The key consideration for any founder is to carefully negotiate these terms and ensure they do not fundamentally undermine the company's long-term growth strategy. Common Venture Debt Covenants and Their Implications Covenant Type Objective Borrower Implications & Risks Financial Covenants To ensure the company maintains financial health and sufficient liquidity to service the debt. - Minimum Cash Balance: Requires a certain amount of cash to be held, limiting working capital and investment flexibility. - Revenue Targets: Mandates hitting monthly or quarterly revenue goals, adding pressure on sales and marketing teams. - Burn Rate Caps: Limits the company's negative cash flow, potentially delaying strategic hires or product launches. Negative Covenants To prevent the company from taking actions that would increase the lender's risk exposure. - Restrictions on New Debt: Prevents the company from taking on additional loans without lender consent, which can hinder future fundraising. - Limitations on Asset Sales: Restricts the disposal of major assets, including intellectual property, which may limit strategic flexibility. Affirmative Covenants To ensure transparency and require the company to maintain standard business practices. - Regular Reporting:Requires consistent delivery of financial statements and reports, increasing the administrative burden. - IP Protection: Mandates that the company maintain legal good standing and protect its intellectual property, which is often the loan's collateral. Opportunities: Strategic Use Cases in Healthtech The "Jet Fuel" for Commercialisation Venture debt is an ideal financial instrument for healthtech companies that have successfully navigated the R&D and product development phases and are ready to launch into commercialisation. In this phase, the capital can act as "jet fuel" to accelerate a go-to-market strategy. Funds can be deployed to scale up a sales and marketing team, expand into new geographic markets, or acquire the capital equipment necessary for commercial-scale production. For companies that have started to generate revenue, they can use these self-sustaining cash flows to service the debt, creating a more sustainable and capital-efficient growth model. For life sciences and med-tech companies, venture debt can be used to fund capital-intensive R&D and clinical development. Lenders recognise that these companies often have significant costs and a long path to profitability. Venture debt can be used to accelerate clinical trials, invest in new R&D infrastructure, or fund the acquisition of external clinical assets. It is particularly effective for companies looking to extend their cash runway past a key value inflection point, such as a clinical data readout or the first dosing in a trial. The ability to leverage intellectual property rights as collateral is a powerful opportunity for healthtech companies with strong patent portfolios but limited current revenue, as it allows them to access capital without relinquishing ownership. Case Studies of Successful Healthtech Deployments Real-world examples illustrate the strategic application of venture debt in the healthtech sector. Aledade, a company focused on value-based primary care, provides a clear case study of a successful deployment. In 2014, the company secured a small $2 million growth capital term loan from Silicon Valley Bank (SVB) alongside a $4.5 million seed round. As Aledade demonstrated its ability to execute its business plan, SVB expanded its financing to include more debt and even lent against unbilled receivables, providing the credit needed to finance its continued growth. This demonstrates the utility of venture debt not just as a one-time infusion but as an evolving financial partnership. Other companies, such as Marathon Health, Arcus Biosciences, and Disc Medicine, have also used debt financing to accelerate clinical development, invest in new R&D, and strengthen their balance sheets ahead of an IPO. The Nexus of AI and Venture Debt The rise of artificial intelligence (AI) in healthtech is creating a unique and significant opportunity for venture debt. The AI sub-sector is a bright spot in the market, attracting a disproportionately large share of venture capital funding and driving mega-deals exceeding $100 million. AI-enabled startups are raising larger rounds at higher valuations, creating a class of companies with more capital to leverage and a more robust financial profile for lenders. The reason for this alignment is that many of the most funded AI applications are focused on areas with a clear path to commercialisation and profitability, such as non-clinical workflow automation, clinical workflow improvements, and data infrastructure. These business models provide a clear return on investment for customers and are inherently less risky than a single-asset biotech company tied to a binary regulatory outcome. This shift in the business model's risk profile makes these companies highly attractive to venture debt lenders. The surge in AI funding has a cascading effect on the venture debt market, creating a positive feedback loop. Large equity rounds for AI companies make them more viable candidates for venture debt, which in turn allows them to extend their runway and achieve milestones that justify even higher valuations for the next equity round. This suggests that the growth of venture debt in healthtech is inextricably linked to the continued maturation and commercial success of AI-driven solutions. The Future of Venture Debt in Healthtech Macroeconomic Trends and Market Projections The venture debt market, much like the broader venture capital ecosystem, is highly cyclical. After four consecutive years of over $30 billion in activity, the market plunged in 2023, mirroring a broader downturn in venture capital funding due to rising interest rates and risk aversion. However, this period of contraction appears to be a correction rather than a collapse. Projections for 2024 and beyond indicate a partial bounce-back, with venture debt expected to continue its growth as an asset class over the medium term. As traditional VC funding has waned and equity has become more expensive and dilutive, venture debt has emerged as a strategic and increasingly popular financing option for later-stage startups. This market normalisation is characterised by a shift from a "growth-at-all-costs" mindset to one focused on "outcomes-plus-durability," favouring companies with stronger business fundamentals and a clearer path to profitability. The Growing Specialisation of Lenders The complexities of the healthtech and life sciences sectors demand a specialized approach to lending. The future of venture debt in this industry is marked by a trend toward lenders with deep, sector-specific expertise and a patient, long-term perspective. These specialised firms, such as Hercules Capital, understand the unique challenges of R&D cycles, the value of intellectual property as collateral, and the nuances of the regulatory environment. They often work in close partnership with top-tier venture capital firms that have a proven track record of success and committed capital for follow-on investments. This collaborative relationship is a critical component of the underwriting process and helps to de-risk investments for the lender while providing strategic support for the borrower. Enduring and Emerging Drivers of Growth The long-term growth of venture debt in healthtech is supported by several key trends. The healthtech market itself continues to mature, with a trend toward platform-enabled ecosystems and a focus on solutions that provide tangible value, particularly in addressing back-office inefficiencies. The industry's shift to value-based care, which rewards positive patient outcomes, creates a foundation for companies with stable, outcomes-linked revenue models, making them more attractive to both equity and debt investors.Furthermore, regulatory and reimbursement clarity for emerging technologies like AI and telehealth reduces the risk for both investors and companies, helping to normalise funding cycles. Navigating Future Headwinds Despite a positive outlook, the venture debt market in healthtech is not without potential headwinds. Ongoing macroeconomic uncertainty and the potential for rising interest rates could make deals smaller, more difficult to obtain, and more expensive in the short term. Additionally, political and regulatory changes, such as shifts in federal healthcare policy or cuts to funding from agencies like the NIH, could introduce new risks and uncertainties for companies dependent on these frameworks. Successfully navigating the future will require founders to be more disciplined, and lenders to be more strategic and specialised, ensuring that capital is deployed to companies with proven, durable business models that can withstand market fluctuations. Conclusion & Recommendations The analysis presented in this report confirms that venture debt is an indispensable and sophisticated financial instrument for the healthtech sector. It provides a unique blend of capital access, ownership preservation, and operational flexibility that is particularly well-suited to the industry's long development cycles and intangible asset base. While it comes with the inherent risks of repayment obligations, restrictive covenants, and the burden of debt, its strategic use can significantly accelerate growth and enhance a company's overall financial health. The future of this market is bright, driven by the maturation of the digital health industry, the proliferation of specialised lenders, and the transformative impact of AI in creating more bankable business models. Based on this comprehensive analysis, the following recommendations are provided for founders and investors navigating the healthtech financing landscape: For Founders: A Strategic Approach to Venture Debt: Timing is Everything: Founders should consider raising venture debt shortly after a new equity round has closed. This is when the company's financial position is strongest and its leverage is highest, leading to more favorable terms and lower costs. Negotiate Covenants Aggressively: The negotiation of the loan agreement, particularly the covenants, is critical. Founders must ensure that the "rules of engagement" do not unduly restrict their ability to pursue key growth opportunities or make necessary strategic pivots. Seek Specialised Lenders: It is paramount to partner with a lender that has deep, sector-specific expertise in healthtech or life sciences. A lender that understands the unique business model, the value of intellectual property, and the regulatory environment is more likely to offer flexible, well-structured terms and act as a patient partner. For Investors: Optimising the Capital Stack: Strategic Integration: Venture capital investors should view venture debt as a strategic tool to complement their equity investments. Encouraging portfolio companies to use debt to extend their runway and achieve milestones can reduce the fund's overall capital requirements for a given company and lead to higher-value exit opportunities. Lender Due Diligence: Prior to a deal, investors should perform rigorous due diligence on potential venture debt partners, focusing on their track record in the healthtech sector and their behaviour during market downturns. Partnering with a reputable and tested lender can mitigate future risks for the portfolio company. Focus on Fundamentals: In a disciplined market, both equity and debt investors should prioritize companies with strong fundamentals and a clear path to profitability. The rise of AI-enabled solutions that demonstrate measurable cost savings and streamlined workflows presents a prime opportunity to invest in a new class of healthtech ventures that are inherently well-suited for a sophisticated mix of equity and debt financing. Nelson Advisors > MedTech and Healthcare Technology M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech and MedTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech#HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech and MedTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk